Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(414 intermediate revisions by 3 users not shown)
Line 1: Line 1:
<!doctype html>
'''Abbreviations'''
<html lang="en">
<head>
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Myeloma - Cancer Stat Facts</title>


<link rel="stylesheet" href="/bootstrap/css/bootstrap.min.css" />
ACTH: Adrenocorticotropic hormone, ARR: Aldosterone-renin ratio, CAM: Cellular adhesion molecules, ERCP: Endoscopic retrograde cholangiopancreatography, ESR: Erythrocyte sedimentation rate, CT: Computerized tomography, Fluorescence in situ hybridization, FDG: Fluorodeoxyglucose, FSH: Follicle stimulating hormone, GI: Gastrointestinal, H&E stain: Hematoxylin and eosin stain, LCA: Leukocyte common antigen, LDH: Lactate dehydrogenase, LH: Luteinizing hormone, MEN: Multiple endocrine neoplasia, MRCP: Magnetic resonance cholangiopancreatography, MRI: Magnetic resonance imaging, N/A: Not applicable/Not available, N/L: Normal, PAS stain: Periodic acid–Schiff stain, PET: Position emission tomography, PGP: Protein gene product 9.5, TB: Tuberculosis, U/S: Ultrasound, ZF: Zona fasciculata, ZG: Zona granulosa, ZR: Zona reticularis.
<link rel="stylesheet" href="/s/base.css" />
{| class="wikitable"
<link rel="stylesheet" href="/s/styles.css" />
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Adrenal Cortex
<link rel="stylesheet" type="text/css" href="/s/jquery.qtip.min.css">
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Adrenal [[Adrenal adenoma|Adenoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Aldosterone]]<br><ref name="pmid26867466">{{cite journal |vauthors=Park JJ, Park BK, Kim CK |title=Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses |journal=Br J Radiol |volume=89 |issue=1062 |pages=20151018 |date=June 2016 |pmid=26867466 |pmc=5258164 |doi=10.1259/bjr.20151018 |url=}}</ref><ref name="pmid25958045">{{cite journal |vauthors=Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P |title=Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas |journal=Mol. Cell. Endocrinol. |volume=411 |issue= |pages=146–54 |date=August 2015 |pmid=25958045 |pmc=4474471 |doi=10.1016/j.mce.2015.04.022 |url=}}</ref><ref name="pmid20498828">{{cite journal |vauthors=Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD |title=Laboratory investigation of primary aldosteronism |journal=Clin Biochem Rev |volume=31 |issue=2 |pages=39–56 |date=May 2010 |pmid=20498828 |pmc=2874431 |doi= |url=}}</ref><ref name="pmid24605256">{{cite journal |vauthors=Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C |title=Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging |journal=J Clin Imaging Sci |volume=3 |issue= |pages=61 |date=2013 |pmid=24605256 |pmc=3935261 |doi=10.4103/2156-7514.124088 |url=}}</ref>
|
* [[Headache]]
* [[Vision]] problems
* [[Muscle]] [[cramps]]
* [[Muscle]] weakness & [[cramps]]
* [[Numbness]]
* Temporary [[paralysis]]
* [[Polyuria]] and [[polydipsia]]
|
* [[Hypertension]]
* [[Refractory hypertension]]
|
* [[Hypokalemia]]
* [[Alkalosis]]
* ↑ [[Plasma]] [[aldosterone]]
* ↓ [[Plasma]] [[Renin]]
* ↑ ARR
|
* Single or multiple [[nodules]]
* Encapsulated
* Abundant clear [[cytoplasm]]
* Uniforming [[nuclei]]
* [[Histopathology]] may resemble:
** [[Zona fasciculata|ZF]] (large, [[lipid]]-laden clear [[cells]])
** [[Zona fasciculata|ZG]] (small, compact [[cells]] with moderate amount of [[lipid]])
** [[Zona reticularis|ZR]] (lipid-sparse [[cytoplasm]])
|
* [[Fludrocortisone]] suppression testing (Gold standard)
* Oral [[Sodium]] loading
* [[Saline]] infusion testing
* [[Captopril]] test
* [[Adrenal venous sampling]]
* Posture test
* [[Genetic testing]]
* [[Immunohistochemical staining]]
*
|
* [[Adrenal]] [[mass]] or [[nodule]]
|
* [[nodule|Adrenal]] [[mass]] or nodule
* [[nodule|Unilateral or bilateral]] [[adrenal]] [[atrophy]]
* [[nodule|Hypodense]] [[mass]]
|
* Iso and low [[FDG]] uptake compared with [[liver]]
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* [[Glucocorticoid]]-Remediable [[Aldosteronism]] responds to [[glucocorticoids]]
* Higher [[cardiovascular]] and [[cerebrovascular]] [[morbidity]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cortisol]]<br><ref name="pmid26867466">{{cite journal |vauthors=Park JJ, Park BK, Kim CK |title=Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses |journal=Br J Radiol |volume=89 |issue=1062 |pages=20151018 |date=June 2016 |pmid=26867466 |pmc=5258164 |doi=10.1259/bjr.20151018 |url=}}</ref><ref name="pmid18493137">{{cite journal |vauthors=Stratakis CA |title=Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome) |journal=Endocr Dev |volume=13 |issue= |pages=117–32 |date=2008 |pmid=18493137 |pmc=3132884 |doi=10.1159/000134829 |url=}}</ref><ref name="pmid25871963">{{cite journal |vauthors=Zilbermint M, Stratakis CA |title=Protein kinase A defects and cortisol-producing adrenal tumors |journal=Curr Opin Endocrinol Diabetes Obes |volume=22 |issue=3 |pages=157–62 |date=June 2015 |pmid=25871963 |pmc=4560837 |doi=10.1097/MED.0000000000000149 |url=}}</ref><ref name="pmid29685132">{{cite journal |vauthors=Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J |title=ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures |journal=BMC Endocr Disord |volume=18 |issue=1 |pages=22 |date=April 2018 |pmid=29685132 |pmc=5913873 |doi=10.1186/s12902-018-0250-6 |url=}}</ref>
|
* [[Weight]] gain
* [[Growth retardation]]
* [[Headache]]
* [[Amenorrhea]]
* [[Virilization]] (rare)
* [[Acne]]
* Violaceous [[striae]]
* [[Acanthosis nigricans]]
* [[Sleep]] disruption
* [[Mental]] changes
* [[Muscular]] weakneness
|
* [[Hypertension]]
* [[Hirsutism]]
* [[Hypogonadism]]
* [[Growth retardation]]
* [[Facial]] plethora
* [[Acne]]
* [[Striae]]
* [[Bruising]]
* [[Acanthosis nigricans]]
* [[Mental]] changes
* [[Muscular]] weakneness
|
* ↑ [[Plasma]] [[cortisol]]
* ↑ 24 Hour [[urinary]] [[cortisol]]
* ↓ or inappropriately normal [[plasma]] [[ACTH]]
* ↑ [[Blood]] [[glucose]]
|
* Yellow [[fat]]
* Brown [[discoloration]]
* Large [[cells]] with increased [[lipid]] contetnt (''[[zona fasciculata]])''
* May contain [[pigment]] ([[lipofuscin]])
* Adjacent [[Atrophy|atrophied]] [[cells]]
* [[Hemorrhage]] and [[calcification]] (Pre-[[malignant]] [[lesions]])
|
* Diurnal [[plasma]] [[cortisol]] variation
* Low dose and high dose [[dexamethasone suppression test]]
* [[Dexamethasone]]-[[CRH]] test
* Adrenal venous sampling
* [[Genetic testing]]
* [[Immunohistochemical staining]]
* [[Dual energy X-ray absorptiometry|Dual-energy X-ray absorptiometry]]
|
* [[Adrenal]] [[mass]] or [[nodule]]
* ↑ [[Fat]]
|
* [[Adrenal]] [[mass]] or [[nodule]]
* Unilateral or bilateral [[adrenal]] [[atrophy]]
* ↑ [[Fat]]
* Hypodense [[mass]]
|
* Iso and low [[FDG]] uptake compared with [[liver]]
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* Associated with [[Carney complex]]
* Associated with [[Multiple endocrine neoplasia type 1|MEN-1]]
* [[Plasma]] levels of [[cortisol]] and [[ACTH]] may show false positive and false negative results due to normal diurnal [[hormonal]] variation
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Androgens]]<br><ref name="pmid24605256">{{cite journal |vauthors=Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C |title=Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging |journal=J Clin Imaging Sci |volume=3 |issue= |pages=61 |date=2013 |pmid=24605256 |pmc=3935261 |doi=10.4103/2156-7514.124088 |url=}}</ref><ref name="pmid16278716">{{cite journal |vauthors=Arnold DT, Reed JB, Burt K |title=Evaluation and management of the incidental adrenal mass |journal=Proc (Bayl Univ Med Cent) |volume=16 |issue=1 |pages=7–12 |date=January 2003 |pmid=16278716 |pmc=1200803 |doi= |url=}}</ref><ref name="pmid23819074">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J |title=Pure androgen-secreting adrenal adenoma associated with resistant hypertension |journal=Case Rep Endocrinol |volume=2013 |issue= |pages=356086 |date=2013 |pmid=23819074 |pmc=3681270 |doi=10.1155/2013/356086 |url=}}</ref><ref name="pmid30674304">{{cite journal |vauthors=Zhou WB, Chen N, Li CJ |title=A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman |journal=BMC Endocr Disord |volume=19 |issue=1 |pages=14 |date=January 2019 |pmid=30674304 |pmc=6343319 |doi=10.1186/s12902-019-0342-y |url=}}</ref>
|
* [[Hirsutism]]
* [[Virilization]]
* [[Amenorrhea]]
* [[Precocious puberty]]
* [[Testicular]] [[atrophy]] & diminished [[libido]] ([[male]])
|
* [[Clitorimegaly]]
* [[Male]] pattern [[baldness]]
* [[Resistant hypertension]]
* [[Gynecomastia]]
|
* ↑ [[Serum]] [[testosterone]]
* ↑ [[Serum]] [[androstenedione]]
* ↑ [[Serum]] [[dehydroepiandrosterone sulfate]] ([[DHEA-S]])
* ↑ [[Urine]] 17-ketosteroids
* ↑ [[Plasma]] and [[urine]] [[estrogens]]


<link rel="stylesheet" href="/s/print.css" media="print" />
*
|
* Pale tan to brown
* Pseudocapsule or the [[fibrous]] [[capsule]]
* Nesting, alveolar, cords, [[trabeculae]]
* [[Eosinophilic]] [[cytoplasm]]
* May see clear, vacuolated [[cytoplasm]]


<script src="/toolbox/javascript/jquery-1.12.4.min.js"></script>
*
<script src="/j/jquery.qtip.min.js" type="text/javascript"></script>
|
* [[FSH]], [[LH]], [[prolactin]] levels
* [[Cortisol]] levels
* [[FDG]] [[PET]]/[[CT]]
* [[Pelvic]] [[Ultrasound]]
* [[Adrenal Venous sampling]]
|
* Well-defined
* Solid [[mass]]
|
* Homogeneous enhancement ([[CT]] [[contrast]])
|
* N/A
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* Extremely rare
* Most [[androgen]] secreting [[adenomas]] are mixed [[tumors]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Non-functional<br><ref name="pmid26867466">{{cite journal |vauthors=Park JJ, Park BK, Kim CK |title=Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses |journal=Br J Radiol |volume=89 |issue=1062 |pages=20151018 |date=June 2016 |pmid=26867466 |doi=10.1259/bjr.20151018 |url=}}</ref><ref name="pmid27479926">{{cite journal |vauthors=Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A |title="Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study |journal=Ann. Intern. Med. |volume=165 |issue=8 |pages=533–542 |date=October 2016 |pmid=27479926 |pmc=5453639 |doi=10.7326/M16-0547 |url=}}</ref><ref name="pmid20823463">{{cite journal |vauthors=Nieman LK |title=Approach to the patient with an adrenal incidentaloma |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4106–13 |date=September 2010 |pmid=20823463 |pmc=2936073 |doi=10.1210/jc.2010-0457 |url=}}</ref><ref name="pmid23255953">{{cite journal |vauthors=Li B, Guo Q, Yang H, Guan J |title=Giant non-functional adrenal adenoma: A case report |journal=Oncol Lett |volume=5 |issue=1 |pages=378–380 |date=January 2013 |pmid=23255953 |pmc=3525484 |doi=10.3892/ol.2012.978 |url=}}</ref>
|
* Asymptomatic
* [[Abdominal]] [[pain]]
* [[Abdominal]] distenstion
* [[Nausea]]/[[vomiting]]
* Sub-clinical [[Cushing syndrome]]
* Sub-clinical [[hyperaldosteronism]]
|
* Asymptomatic
* [[Abdominal]] asymmetry
* [[Abdominal]] [[mass]]
* Sub-clinical [[Cushing syndrome]]
* Sub-clinical [[hyperaldosteronism]]
|
* N/L
* ↓ [[Adrenal]] [[hormones]]
* ↑ [[Serum]] [[cortisol]] (sub-clinical)
* ↑ [[Serum]] [[aldosterone]](sub-clinical)
* ↑ [[Serum]] [[androgens]] (sub-clinical)
|
* Well-defined margins
* Large monomorphic [[cells]]
* Abundant/foamy [[cytoplasm]]
* Typically resemble normal [[adrenal]] [[histology]]
* May see [[hemorrhage]] & [[necrosis]]
|
* [[Adrenal]] [[hormones]] levels
* [[Blood]] [[glucose]] level
* [[Plasma]] [[catecholamines]] and [[urinary]] [[metanephrines]]
* ARR
* [[Immunohistochemical staining]]
|
* Solid, well defined [[mass]]
|
* High [[lipid]] content and adjacent compression
|
* N/A
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* 2-fold increased risk for [[Diabetes mellitus]] in some studies
* Work up must exclude [[Cushing syndrome]], [[pheochromocytoma]] and [[adrenal carcinoma]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Adrenal [[Adrenal cancer|Carcinoma]]<br><ref name="pmid20823463">{{cite journal |vauthors=Nieman LK |title=Approach to the patient with an adrenal incidentaloma |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4106–13 |date=September 2010 |pmid=20823463 |pmc=2936073 |doi=10.1210/jc.2010-0457 |url=}}</ref><ref name="pmid26191527">{{cite journal |vauthors=Libé R |title=Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment |journal=Front Cell Dev Biol |volume=3 |issue= |pages=45 |date=2015 |pmid=26191527 |pmc=4490795 |doi=10.3389/fcell.2015.00045 |url=}}</ref><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid24423978">{{cite journal |vauthors=Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD |title=Adrenocortical carcinoma |journal=Endocr. Rev. |volume=35 |issue=2 |pages=282–326 |date=April 2014 |pmid=24423978 |pmc=3963263 |doi=10.1210/er.2013-1029 |url=}}</ref><ref name="pmid24102952">{{cite journal |vauthors=Wang C, Sun Y, Wu H, Zhao D, Chen J |title=Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers |journal=Histopathology |volume=64 |issue=4 |pages=567–76 |date=March 2014 |pmid=24102952 |pmc=4282325 |doi=10.1111/his.12283 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Cortisol]]
* [[Aldosterone]]
* [[Androgens]]
* Non-functional
* [[Erythropoietin]]
|
* Symptoms of [[adrenal]] [[hormones]] excess as mentioned in [[adrenal adenoma]]
* Constitutional [[symptoms]] such as [[cachexia]], [[night sweats]], [[fever]]
* Localized [[symptoms]] such as [[abdominal]] [[pain]], [[mass]], fullness, early [[satiety]]
|
* [[Hypertension]]
* Signs of [[Adrenal gland|adrenal hormones]] excess as mentioned in [[adrenal adenoma]]
* Constitutional
* Localized [[signs]] such as [[abdominal]] [[mass]],[[abdominal]] [[distension]]
|
* N/L
* ↑ [[Serum]] [[cortisol]]
* ↑ [[Serum]] [[aldosterone]]
* ↑ [[Serum]] [[androgens]] 
* [[Hypokalemia]] 
* [[Alkalosis]]
* ↑ ARR
* ↑ [[Blood]] [[glucose]]
|
* Brown to orange to yellow
* [[Necrosis]] & [[mitosis]]
* [[Hypercellular]] & [[solid]] and/or diffuse [[growth]] pattern
* Low to high [[lipid]] content
* [[Nuclear]] [[pleomorphism]]
* Lymphovascular [[invasion]]
|
* [[Serum]] [[ACTH]]
* Low dose and high dose [[dexamethasone suppression test]]
* [[Urinary]] [[adrenal]] [[metabolites]]
* [[Spectroscopy|Proton MR spectroscopy]]
* [<sup>11</sup>C]MTO [[PET]]
* [[Immunohistochemical staining]]
|
* N/A
|
* Heterogeneous enhancement
|
* Heterogeneous mass with intense [[FDG]] uptake greater than [[liver]]
|
* Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted)
|
* May cause [[hypoglycemia]] (Anderson's syndrome}
* May be associated with:
** [[Hyperreninemic hypoaldosteronism|Hyperreninemic]]
** [[Hyperaldosteronism]]
** [[Erythropoietin]]-associated [[polycythemia]]
** [[Leukocytosis]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Adrenal [[Adrenal hyperplasia|Hyperplasia]]<br><ref name="pmid25958045">{{cite journal |vauthors=Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P |title=Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas |journal=Mol. Cell. Endocrinol. |volume=411 |issue= |pages=146–54 |date=August 2015 |pmid=25958045 |pmc=4474471 |doi=10.1016/j.mce.2015.04.022 |url=}}</ref><ref name="pmid18493137">{{cite journal |vauthors=Stratakis CA |title=Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome) |journal=Endocr Dev |volume=13 |issue= |pages=117–32 |date=2008 |pmid=18493137 |pmc=3132884 |doi=10.1159/000134829 |url=}}</ref><ref name="pmid24605256">{{cite journal |vauthors=Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C |title=Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging |journal=J Clin Imaging Sci |volume=3 |issue= |pages=61 |date=2013 |pmid=24605256 |pmc=3935261 |doi=10.4103/2156-7514.124088 |url=}}</ref><ref name="pmid16278716">{{cite journal |vauthors=Arnold DT, Reed JB, Burt K |title=Evaluation and management of the incidental adrenal mass |journal=Proc (Bayl Univ Med Cent) |volume=16 |issue=1 |pages=7–12 |date=January 2003 |pmid=16278716 |pmc=1200803 |doi= |url=}}</ref><ref name="pmid23819074">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J |title=Pure androgen-secreting adrenal adenoma associated with resistant hypertension |journal=Case Rep Endocrinol |volume=2013 |issue= |pages=356086 |date=2013 |pmid=23819074 |pmc=3681270 |doi=10.1155/2013/356086 |url=}}</ref><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid28707538">{{cite journal |vauthors=Michelle M A, Jensen CT, Habra MA, Menias CO, Shaaban AM, Wagner-Bartak NA, Roman-Colon AM, Elsayes KM |title=Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics |journal=Br J Radiol |volume=90 |issue=1079 |pages=20170330 |date=November 2017 |pmid=28707538 |pmc=5963387 |doi=10.1259/bjr.20170330 |url=}}</ref><ref name="pmid26770569">{{cite journal |vauthors=Zhang Y, Li H |title=Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease |journal=Int J Clin Exp Med |volume=8 |issue=10 |pages=19311–7 |date=2015 |pmid=26770569 |pmc=4694469 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Cortisol]] (most common)
* [[Aldosterone]]
* [[Androgens]]
* Non-functional
|
* Depending on the product secreted, may present as:
** [[Cushing syndrome]]
** [[Hyperaldosteronism]]
** [[Virilization]]
** [[Hirsutism]]
** [[Menstrual irregularities]]
** [[Testicular]] [[atrophy]]
** Diminished [[libido]]
* Localized [[symptoms]] such as [[abdominal]] [[pain]], [[mass]], [[fullness]], early [[satiety]]
|
* Depending on the product secreted, may present as:
** [[Cushing syndrome]]
** [[Hyperaldosteronism]]
** [[Virilization]]
** [[Hirsutism]]
** [[Menstrual irregularities]]
** [[Testicular]] [[atrophy]]
** [[Gynecomastia]]
* Localized [[symptoms]] such as [[abdominal]] [[pain]], [[mass]], [[fullness]], early [[satiety]]
|
* ↑ [[Serum]] [[cortisol]]
* ↑ [[Serum]] [[aldosterone]]
* ↑ [[Serum]] [[androgens]] 
* [[Hypokalemia]] 
* [[Alkalosis]]
* ↑ ARR
* ↑ [[Blood]] [[glucose]]
* ↑ [[Serum]] [[testosterone]]
* ↑ [[Serum]] [[androstenedione]]
* ↑ [[Serum]] [[dehydroepiandrosterone sulfate]] ([[DHEA-S]])
* ↑ [[Plasma]] and [[urine]] [[estrogens]]
|


<!-------------------------Meta Tags for Social Sharing---------------------------------->
* Diffuse or [[nodular]] enlargement
<!----TWITTER---->
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@NCICancerStats" />
<meta name="twitter:creator" content="@NCICancerStats" />
<meta name="twitter:image" content="https://seer.cancer.gov/i/tile-fact.jpg" />


<!----Open Graph---->
* Increased thickness of [[zona reticularis]] and [[zona fasciculata]]
<meta property="og:type" content="article" />
* Large polygonal [[cells]] with/without [[lipid]] depletion
<meta property="og:image" content="https://seer.cancer.gov/i/tile-fact.jpg" />
* May contain [[pigment]] ([[lipofuscin]])
<meta property="og:site_name" content="SEER" />
* [[endocrine]] [[atypia]]
<!--custom_head--><meta name="description" content="Myeloma Statistics"/>
* Small [[nodules]]
<link rel="stylesheet" href="/toolbox/css/nvd3/nv.d3.css"  type="text/css">
|
<link rel="stylesheet" href="/statfacts/html/s/nv.d3.factsheets.css" type="text/css">
* [[Adrenal venous sampling]]
<link rel="stylesheet" href="s/nv.d3.factsheets.css"  type="text/css">
* [[Pelvic]] & [[pituitary]] [[imaging]]
<!--
* [[Genetic testing]]
To avoid the flash of the default data when waiting for the JS to kick in and create the SVGs, we hide the data accessibly in styles.css and then only show it to visual users if there is no JS as a fallback. Screen readers get access to it all times. These styles bring the data back into view and supress the SVG containers.
* [[Fludrocortisone]] suppression testing
-->
* [[Saline]] infusion testing
<noscript>
* Diurnal [[plasma]] [[cortisol]] variation
<style>
* Low dose and high dose [[dexamethasone suppression test]]
.defaultData { position: relative; width: auto; height: auto; padding: 0; margin: 0; overflow: auto; clip: none; border: 0; }
* [[FSH]], [[LH]], [[prolactin]] levels
.svgEnhance { display: none; }
* [[Cortisol]] levels
</style>
|
</noscript>
* [[Adrenal]] [[mass]]
* Unilateral or bilateral [[adrenal]] enlargement or thickening
|
* Unilateral or bilateral [[adrenal]] enlargement or thickening
* [[Density]] is same as that of normal [[adrenal gland]]
|
* N/A
|
* Unilateral or bilateral [[adrenal]] enlargement or thickening
* Signaling is same as that of normal [[adrenal gland]]
|
* [[Congenital adrenal hyperplasia]] presents in [[children]]/young adults
* Associated with [[Carney complex]]
* [[Plasma]] levels of [[cortisol]] and [[ACTH]] may show false positive and false negative results due to normal diurnal [[hormonal]] variation
|+
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Medulla
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pheochromocytoma]]<br><ref name="pmid24636754">{{cite journal |vauthors=Martucci VL, Pacak K |title=Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment |journal=Curr Probl Cancer |volume=38 |issue=1 |pages=7–41 |date=2014 |pmid=24636754 |pmc=3992879 |doi=10.1016/j.currproblcancer.2014.01.001 |url=}}</ref><ref name="pmid20541673">{{cite journal |vauthors=Kantorovich V, Pacak K |title=Pheochromocytoma and paraganglioma |journal=Prog. Brain Res. |volume=182 |issue= |pages=343–73 |date=2010 |pmid=20541673 |pmc=4714594 |doi=10.1016/S0079-6123(10)82015-1 |url=}}</ref><ref name="pmid19605896">{{cite journal |vauthors=Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV |title=Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus) |journal=Vet. Pathol. |volume=46 |issue=6 |pages=1221–9 |date=November 2009 |pmid=19605896 |doi=10.1354/vp.09-VP-0022-M-FL |url=}}</ref><ref name="pmid19120142">{{cite journal |vauthors=Kantorovich V, Eisenhofer G, Pacak K |title=Pheochromocytoma: an endocrine stress mimicking disorder |journal=Ann. N. Y. Acad. Sci. |volume=1148 |issue= |pages=462–8 |date=December 2008 |pmid=19120142 |pmc=2693284 |doi=10.1196/annals.1410.081 |url=}}</ref><ref name="pmid25332315">{{cite journal |vauthors=Eisenhofer G, Peitzsch M |title=Laboratory evaluation of pheochromocytoma and paraganglioma |journal=Clin. Chem. |volume=60 |issue=12 |pages=1486–99 |date=December 2014 |pmid=25332315 |doi=10.1373/clinchem.2014.224832 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Catecholamines]]
|
*[[Headaches]]
*[[Palpitations]]
*Excessive [[sweating]]
*[[Anxiety]]
*[[Pallor]]
*Pain in [[chest]]/[[abdomen]]
*[[Weakness]], [[fatigue]]
*[[Nausea]]/[[vomiting]]
*[[Dizziness]]
*[[Paresthesias]]
*[[Constipation]] (rarely [[diarrhea]])
*[[Visual disturbance]]
|
*[[Hypertension]]
*Postural [[hypotension]]
*[[Tachycardia]] or reflex [[bradycardia]]
*Tremulousness
*[[Pallor]]
*[[Flushing]] (rare)
*[[Weight]] loss
*Fasting [[hyperglycaemia]]
*Decreased [[GI]] [[motility]]
*[[Pallor]]
*↑ [[Respiratory rate]]
*[[Psychosis]]
|
* ↑ [[Plasma]] and [[urine]] [[catecholamines]] (Gold standard)
* ↑ [[Plasma]] and [[urine]] [[metanephrines]] (Gold standard)
* ↑ [[Chromogranin A]]
* ↑ [[Plasma]] [[methoxytyramine]]
|
*Loosely cohesive clusters
*Scattered [[tumor]] [[cells]] with prominent anisokaryosis, abundant [[eosinophilic]] granular [[cytoplasm]] and indistinct [[cell]] borders
*Occasional bi-nucleate [[cells]]
|
*Genetic testing
*Provacative [[glucagon]] test
*[[Clonidine]] suppression test
*Metaiodobenzyl-guanidine [[scintigraphy]]
*[[PET]] scan
*[[Octereoscan]]
|
*[[Cystic]] or solid with [[necrotic]] areas or [[hemorrhages]]
|
* Heterogeneous appearance, often with some [[cystic]] areas.
* [[Calcification]] or [[hemorrhage]] may also be present
|
* N/A
|
* T2-bright lesions, with/without [[cystic]] or [[necrotic]] components
|
*May mimic [[panic attack]]
*May be associated with  [[Von Hippel-Lindau disease]],  [[MEN type 2]] and [[neurofibromatosis type 1]].
*Arise from the [[chromaffin cells]]
*[[Stain|Stains]] positive for
** [[Chromogranin A]] (CGA)
** Protein gene product (PGP) 9.5
** [[Synaptophysin]] (SYN)
** [[CD56]] ([[CAM|N-CAM]])
** [[Glial fibrillary acidic protein]] ([[GFAP]])
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Neuroblastoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid25154816">{{cite journal |vauthors=Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG |title=Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project |journal=J. Clin. Oncol. |volume=32 |issue=28 |pages=3169–76 |date=October 2014 |pmid=25154816 |pmc=4171360 |doi=10.1200/JCO.2014.56.1621 |url=}}</ref><ref name="pmid25254086">{{cite journal |vauthors=Bordbar M, Tasbihi M, Kamfiroozi R, Haghpanah S |title=Epidemiological and clinical characteristics of neuroblastoma in southern iran |journal=Iran J Ped Hematol Oncol |volume=4 |issue=3 |pages=89–96 |date=2014 |pmid=25254086 |pmc=4173027 |doi= |url=}}</ref><ref name="pmid24563879">{{cite journal |vauthors=Skoura E, Oikonomopoulos G, Vasileiou S, Kyprianou D, Koumakis G, Datseris IE |title=(18)F-FDG-PET/CT, (123)I-MIBG and (99m)Tc-MDP whole-body scans, in detecting recurrence of an adult adrenal neuroblastoma |journal=Hell J Nucl Med |volume=17 |issue=1 |pages=58–61 |date=2014 |pmid=24563879 |doi=10.1967/s002449910116 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Catecholamines]]
|
* Constitutional
* Failure to thrive
* [[Abdominal]] [[pain]]
* [[Diarrhea]]
* [[Constipation]]
* [[Dyspnea]]
* Prolonged [[cough]]
* [[Strabismus]]
* [[Proptosis]]
|
* [[Abdominal]] [[mass]]
* [[Pallor]]
* [[Tachycardia]]
* [[Hypertension]]
* Failure to thrive
* [[Strabismus]]
* [[Proptosis]]
|
* N/L
* Slight elevation in [[catecholamines]]
* ↑ [[Urinary]] [[metanephrines]]
* [[Anemia]]
* ↑ [[Ferritin]]
* ↑ [[LDH]]
* [[Thrombocytosis]]
|
* Pathological examinations are gold standard.
* Cells may show:
** Undifferentiation
** Poor differentiation
** Differentiating [[neuroblasts]]
* [[Necrosis]]
* Salt and pepper [[chromatin]]
* [[Spindle]]-like [[fibers]]
|
* [[Immunohistochemical staining]]
* [[PET]] scan
*[[Octereoscan]]
*<sup>131</sup>I-metaiodobenzylguanidine (MIBG) [[scintigraphy]]
*[[FISH]]
*[[Genetic testing]]
|
* Large mass
* May cross midline
|
* Large mass extending across the midline
* Heterogeneous enhancement
* [[Calcification]] & [[hemorrhage]]
|
* N/A
|
* [[Calcification]] & [[hemorrhage]]
* Non-homogeneous and hyperintense
* Hypointense (T1-weighted)
|[[Stain|Stains]] positive for:
* [[Chromogranin A]] (CGA)
* Protein gene product (PGP) 9.5
* [[Neuron-specific enolase]]
* [[Synaptophysin]] ([[Synaptophysin|SYN]])
* [[CD56]] & [[CD57]]
* [[Glial fibrillary acidic protein]] ([[GFAP]])


<style>
*
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ganglioneuroma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid29085827">{{cite journal |vauthors=Mylonas KS, Schizas D, Economopoulos KP |title=Adrenal ganglioneuroma: What you need to know |journal=World J Clin Cases |volume=5 |issue=10 |pages=373–377 |date=October 2017 |pmid=29085827 |pmc=5648998 |doi=10.12998/wjcc.v5.i10.373 |url=}}</ref><ref name="pmid24779851">{{cite journal |vauthors=Adas M, Koc B, Adas G, Ozulker F, Aydin T |title=Ganglioneuroma presenting as an adrenal incidentaloma: a case report |journal=J Med Case Rep |volume=8 |issue= |pages=131 |date=April 2014 |pmid=24779851 |pmc=4031973 |doi=10.1186/1752-1947-8-131 |url=}}</ref><ref name="pmid23661526">{{cite journal |vauthors=Li J, Yang CH, Li LM |title=Diagnosis and treatment of 29 cases of adrenal ganglioneuroma |journal=Eur Rev Med Pharmacol Sci |volume=17 |issue=8 |pages=1110–3 |date=April 2013 |pmid=23661526 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Catecholamines]]
* [[VIP]]
* [[Cortisol]]
* [[Androgens]]
|
* Asymptomatic
* [[Abdominal]] [[pain]]
* [[Diarrhea]]
|
* N/L
* [[Abdominal]] [[mass]]
* [[Hypertension]]
|
* N/L
* ↑ [[Plasma]] and [[urinary]] [[catecholamine]]
* ↑ [[VIP]]
* ↑ [[Cortisol]] and [[testosterone]]
|
* Pathological examinations are gold standard.
* Mature type: mature [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]]
* Maturing type: [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]] with varying [[maturation]]
|
* Pathological examinations are gold standard.
* [[Ultrasound]]
* [[Immunohistochemical staining]]
* <sup>18</sup>F-2-fluoro-deoxy-D-glucose-[[positron emission tomography]] ([[PET]])
|
* N/A
|
* Well-defined, Homogeneous
* Punctate or discrete [[calcification]]
|
* N/A
|
* Hypointense (T1-weighted)
* Varied signal (T2-weighted)
|
[[Stain|Stains]] positive for:
* [[S-100|S100]]
* [[Synaptophysin]]
* [[Neurofilament]] ([[NF]]) [[protein]]
* [[Chromogranin A]]
* [[Glial fibrillary acidic protein]]
* PGP 9.5
* [[Type IV collagen]]
* [[VIP]]
|+
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Stroma
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|+
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lipoma]]/[[Myolipoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid11533079">{{cite journal |vauthors=Lam KY, Lo CY |title=Adrenal lipomatous tumours: a 30 year clinicopathological experience at a single institution |journal=J. Clin. Pathol. |volume=54 |issue=9 |pages=707–12 |date=September 2001 |pmid=11533079 |pmc=1731508 |doi= |url=}}</ref><ref name="pmid24328509">{{cite journal |vauthors=Gershuni VM, Bittner JG, Moley JF, Brunt LM |title=Adrenal myelolipoma: operative indications and outcomes |journal=J Laparoendosc Adv Surg Tech A |volume=24 |issue=1 |pages=8–12 |date=January 2014 |pmid=24328509 |pmc=3931430 |doi=10.1089/lap.2013.0411 |url=}}</ref><ref name="pmid26464739">{{cite journal |vauthors=Luo J, Chen L, Wen Q, Xu L, Chu S, Wang W, Alnemah MM, Fan S |title=Lipoadenoma of the adrenal gland: report of a rare entity and review of literature |journal=Int J Clin Exp Pathol |volume=8 |issue=8 |pages=9693–7 |date=2015 |pmid=26464739 |pmc=4583971 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* Asymptomatic
* [[Abdominal]] [[pain]]
* Back [[pain]]
* [[Fever]]
|
* N/L
* [[Abdominal]] [[mass]]
* [[Fever]]
|
* N/L
|
* Pathological examinations are gold standard.
* Yellow [[adipose tissue]]
* [[Hemorrhagic]] foci
* Islands of [[Hematopoiesis lineages|hematopoietic cells]] ([[myolipoma]]) and mature [[fat cells]] ([[Lipoma]])
|
* [[Renal function tests|RFTs]]
* [[LFTs]]
* [[Urinalysis|Urine analysis]]
* [[Ultrasound]]
|
* Heterogeneous [[mass]]
|
* [[Retro-peritoneal]] [[mass]]
* Well-defined heterogenous enhancement
|
* N/A
|
* High signal
|
* [[Myolipoma]]: mature [[adipose tissue]] and [[haematopoietic]]  elements
* [[Lipoma]]: mature [[fat cells]]
|+
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]]<br><ref name="pmid27006656">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG |title=Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test |journal=Int J Endocrinol |volume=2016 |issue= |pages=9051865 |date=2016 |pmid=27006656 |pmc=4781954 |doi=10.1155/2016/9051865 |url=}}</ref><ref name="pmid15451821">{{cite journal |vauthors=Haddara WM, van Uum SH |title=TB and adrenal insufficiency |journal=CMAJ |volume=171 |issue=7 |pages=710; author reply 710–1 |date=September 2004 |pmid=15451821 |pmc=517840 |doi=10.1503/cmaj.1041046 |url=}}</ref><ref name="pmid26516430">{{cite journal |vauthors=Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW |title=Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status |journal=World J Radiol |volume=7 |issue=10 |pages=336–42 |date=October 2015 |pmid=26516430 |pmc=4620114 |doi=10.4329/wjr.v7.i10.336 |url=}}</ref><ref name="pmid28233510">{{cite journal |vauthors=Vinnard C, Blumberg EA |title=Endocrine and Metabolic Aspects of Tuberculosis |journal=Microbiol Spectr |volume=5 |issue=1 |pages= |date=January 2017 |pmid=28233510 |doi=10.1128/microbiolspec.TNMI7-0035-2016 |url=}}</ref><ref name="pmid23687365">{{cite journal |vauthors=Rajasekharan C, Ajithkumar S, Anto V, Parvathy R |title=Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=May 2013 |pmid=23687365 |doi=10.1136/bcr-2012-008011 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* [[Weakness]]
* [[Malaise]]
* [[Nausea]]
* [[Fatigue]]
* [[Anorexia]]
* [[Abdominal]] [[pain]]
* [[Orthostatic hypotension]]
* [[Constipation]]
* [[Salt]] craving
* [[Adrenal crisis]]
* [[Symptoms]] of [[pulmonary]] [[TB]]
|
* [[Weight loss]]
* [[Hyperpigmentation]] of the [[skin]]
* [[Fever]]
* [[Hypotension]]
* [[Adrenal crisis]]
* [[Signs]] of [[pulmonary tuberculosis]]
|
* [[Anemia]]
* [[Leukocytosis]]
* [[Hyponatremia]]
* [[Hyperkalemia]]
* [[Hypoglycemia]]
* Low early morning [[serum]] [[cortisol]] levels
* Low basal [[urinary]] [[cortisol]]
* ↑ [[ACTH]]
* ↓ [[Aldosterone]]
* ↑ [[Plasma]] [[renin]]
|
* Enlarged, [[necrotic]] [[adrenal glands]]
* Central [[caseous necrosis]]
* Rim of [[granulomatous]] [[inflammatory cells]] ([[Langerhans giant cells]] and [[lymphocytes]])
* Identifiable [[Acid fast|acid-fast stain]]-positive [[bacteria]] with [[Ziehl-Neelsen stain|Ziehl-Neelsen]] or [[Immunofluorescence|fluorescent stains]]
|
* [[Laparoscopic]] [[adrenalectomy]]
* [[Chest X-ray]]
* [[Chest]] [[CT scan]]
* [[Tuberculin test]]
* [[ACTH]] stimulation test
* [[Insulin]] induced [[hypoglycemia]]
* [[Metyrapone]] stimulation tests
|
* Variable
|
* [[Calcification]]
* Hypodense areas
* Rim enhancement
|
* High [[FDG]] uptake by [[adrenal glands]]
|
* [[Calcification]]
* Variable signals
|
* Majority of the cases are secondary to:
** [[Pulmonary TB]]
** [[Genitourinary]] [[TB]]
** [[HIV]] [[infection]]
* May present with [[shock]] with severe [[hypotension]] and [[hypoglycemia]] due to [[glucocorticoid]] insufficiency
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Histoplasmosis]]<br><ref name="pmid27995051">{{cite journal |vauthors=Rog CJ, Rosen DG, Gannon FH |title=Bilateral adrenal histoplasmosis in an immunocompetent man from Texas |journal=Med Mycol Case Rep |volume=14 |issue= |pages=4–7 |date=December 2016 |pmid=27995051 |pmc=5154969 |doi=10.1016/j.mmcr.2016.11.006 |url=}}</ref><ref name="pmid27047312">{{cite journal |vauthors=Wahab NA, Mohd R, Zainudin S, Kamaruddin NA |title=Adrenal involvement in histoplasmosis |journal=EXCLI J |volume=12 |issue= |pages=1–4 |date=2013 |pmid=27047312 |pmc=4817423 |doi= |url=}}</ref><ref name="pmid29888193">{{cite journal |vauthors=May D, Khaled D, Gills J |title=Unilateral adrenal histoplasmosis |journal=Urol Case Rep |volume=19 |issue= |pages=54–56 |date=July 2018 |pmid=29888193 |pmc=5991316 |doi=10.1016/j.eucr.2018.03.010 |url=}}</ref><ref name="pmid29643659">{{cite journal |vauthors=Gupta RK, Majumdar K, Srivastava S, Varakanahalli S, Saran RK |title=Endoscopic Ultrasound-guided Cytodiagnosis of Adrenal Histoplasmosis with Reversible CD4 T-Lymphocytopenia and Jejunal Lymphangiectasia |journal=J Cytol |volume=35 |issue=2 |pages=110–113 |date=2018 |pmid=29643659 |pmc=5885598 |doi=10.4103/JOC.JOC_234_15 |url=}}</ref><ref name="pmid25027093">{{cite journal |vauthors=Padma S, Sreehar S |title=18F FDG PET/CT identifies unsuspected bilateral adrenal histoplasmosis in an elderly immuno compromised patient |journal=Indian J. Med. Res. |volume=139 |issue=5 |pages=786–7 |date=May 2014 |pmid=25027093 |pmc=4140048 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* No [[adrenal]] s[[ymptoms]]
* [[Adrenal insufficiency]]:
** [[Weakness]] & [[malaise]]
** [[Nausea]], [[fatigue]] and [[anorexia]]
** [[Abdominal]] [[pain]]
** [[Orthostatic hypotension]]
** [[Constipation]]
** [[Salt]] craving
* [[Symptoms]] of [[pulmonary]]/[[skin]]/[[bone]] [[histoplasmosis]]
|
* [[Weight loss]]
* [[Hyperpigmentation]] of the [[skin]]
* [[Fever]]
* [[Hypotension]]
* [[Adrenal crisis]]
* [[Signs]] of [[pulmonary]]/[[skin]]/[[bone]] [[histoplasmosis]]
|
* [[Anemia]]
* [[Leukocytosis]]
* [[Hyponatremia]]
* [[Hyperkalemia]]
* [[Hypoglycemia]]


    /* we'll need thinner lines on these pages ' */
* Low early morning [[serum]] [[cortisol]] levels
  .nvd3 g.nv-groups path.nv-line {
* Low basal [[urinary]] [[cortisol]]
      stroke-width: 2px !important;
* ↑ [[ACTH]]
  }
* ↓ [[Aldosterone]]
* ↑ [[Plasma]] [[renin]]
|
* [[Necrotizing]] [[granulomatous]] [[inflammation]] similar to [[tuberculosis]]
* [[Capsulated]] [[yeast]] forms of ''[[Histoplasma]]'' ([[Giemsa stain]])
* ''[[Histoplasma]]'' identification ([[H&E stain]])
* Focal ovoid bodies with a clear halo ([[PAS stain]])
|
* [[Ultrasound]]-guided [[fine needle aspiration]] [[cytology]] ([[Ultrasound|USG]]-[[FNA|FNAC]]) is gold standard.
* [[Laparoscopic]] [[adrenalectomy]]
* [[Endoscopic ultrasound]]
* [[Ultrasound|Abdominal ultrasound]]
* [[Chest X-ray]]
* [[ACTH]] stimulation test
* [[Metyrapone]] stimulation tests
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
* Heterogeneous enhancement
|
* Abnormal [[FDG]] uptake by [[adrenal glands]]
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
* Isointense [[adrenal]] [[mass]] ([[MRI]])
|
* [[Patient]] may exhibit no [[clinical manifestations]] of [[adrenal]] involvement
* Majority of the cases are secondary to:
** [[Pulmonary]] [[histoplasmosis]]
** [[HIV]] [[infection]]
* May present with [[shock]] with severe [[hypotension]] and [[hypoglycemia]] due to [[glucocorticoid]] insufficiency
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cysts]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid28246490">{{cite journal |vauthors=Carsote M, Ghemigian A, Terzea D, Gheorghisan-Galateanu AA, Valea A |title=Cystic adrenal lesions: focus on pediatric population (a review) |journal=Clujul Med |volume=90 |issue=1 |pages=5–12 |date=2017 |pmid=28246490 |doi=10.15386/cjmed-677 |url=}}</ref><ref name="pmid26807295">{{cite journal |vauthors=Słapa RZ, Jakubowski WS, Dobruch-Sobczak K, Kasperlik-Załuska AA |title=Standards of ultrasound imaging of the adrenal glands |journal=J Ultrason |volume=15 |issue=63 |pages=377–87 |date=December 2015 |pmid=26807295 |pmc=4710689 |doi=10.15557/JoU.2015.0035 |url=}}</ref><ref name="pmid29881567">{{cite journal |vauthors=Olaoye IO, Adesina MD, Afolayan EA |title=A giant adrenal cyst with an uncertain preoperative diagnosis causing a dilemma in management |journal=Clin Case Rep |volume=6 |issue=6 |pages=1074–1076 |date=June 2018 |pmid=29881567 |pmc=5986023 |doi=10.1002/ccr3.1519 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* [[Abdominal]] [[pain]]
* [[Abdominal Aortic Aneurysm|Abdominal]] [[mass]]
* [[Abdominal]] fullness
* [[Hematuria]]
* [[Infection]]
* [[Symptoms]] of [[malignancy]] ([[Cystic]] part of other [[tumors]])
|
* [[Abdominal]] [[mass]] & assymetry
* [[Fever]]
* [[Hypertension]] ([[Renal]] compression)
* [[Hypotension]] ([[Hemorrhage]] into [[cyst]])
* [[Signs]] of [[malignancy]] ([[Cystic]] part of other [[tumors]])
|
* N/L
* [[Anemia]]
* [[Leukocytosis]]
|
* [[Vascular]] or [[endothelial]] [[cyst]]: lined by flattened [[endothelial cells]]
* [[Epithelial]]: lined by [[epithelium]]
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* [[Hydatid cyst]]: 3 layers (germinal layer, laminated [[membrane]] and dense [[fibrovascular tissue]])
|
* Complete [[endocrine]] panel
* [<sup>18</sup>F][[FDG]] [[PET]]/[[CT]] (if [[malignancy]] is suspected)
* [[Biopsy]] (if [[malignancy]] is suspected)
* [[ACTH]] stimulation test
|
* Gold standard
* Circumscribed anechoic or hypoechoic mass
|
* Homogeneous [[mass]]
* No enhancement
* [[Calcification]]
* Low density
|
* N/A
|
* High signal
|
* 3 major subtypes
** Pure [[cysts]] ([[vascular]] or [[endothelial]] [[cyst]], [[pseudocyst]] and 'true' [[epithelial]] [[cysts]])
** [[Parasitic cysts]]
** [[Cystic]] part of an otherwise solid [[tumor]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid14747454">{{cite journal |vauthors=Hamilton D, Harris MD, Foweraker J, Gresham GA |title=Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection |journal=J. Clin. Pathol. |volume=57 |issue=2 |pages=208–9 |date=February 2004 |pmid=14747454 |pmc=1770213 |doi= |url=}}</ref><ref name="pmid28828107">{{cite journal |vauthors=Di Serafino M, Severino R, Coppola V, Gioioso M, Rocca R, Lisanti F, Scarano E |title=Nontraumatic adrenal hemorrhage: the adrenal stress |journal=Radiol Case Rep |volume=12 |issue=3 |pages=483–487 |date=September 2017 |pmid=28828107 |pmc=5551907 |doi=10.1016/j.radcr.2017.03.020 |url=}}</ref><ref name="pmid29770310">{{cite journal |vauthors=Ierardi AM, Petrillo M, Patella F, Biondetti P, Fumarola EM, Angileri SA, Pesapane F, Pinto A, Dionigi G, Carrafiello G |title=Interventional radiology of the adrenal glands: current status |journal=Gland Surg |volume=7 |issue=2 |pages=147–165 |date=April 2018 |pmid=29770310 |pmc=5938278 |doi=10.21037/gs.2018.01.04 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* [[Flank]]/back [[pain]]
* [[Weakness]]
* [[Hypovolemic shock]]
* [[Adrenal crisis]] (massive [[hemorrhage]])
* [[Adrenal insufficiency]]
* [[Symptoms]] of underlying [[cause]]
|
* [[Hypotension]]
* [[Abdominal]]/[[flank]] [[mass]]
* [[Hypovolemic shock]]
* [[Adrenal crisis]] (massive [[hemorrhage]])
* [[Adrenal insufficiency]]
* [[Signs]] of underlying cause
|
* [[Anemia]]
* ↓ [[Serum]] and [[urinary]] [[Adrenal Gland|adrenal hormones]] and [[metabolites]]
* Findings related to underlying cause
|
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* Findings related to underlying cause
|
* [[Adrenal]] [[ultrasound]]
* [[ACTH]] stimulation test
* Tests related to underlying cause
|
* Variable
|
* High density (acute [[hemorrhage]])
|
* N/A
|
* Isointense and low signal (Early [[hemorrhage]])
* Hypointense (Late [[hemorrhage]])
|
* Majority of the cases in [[neonantal]] peiod
* Majority of the cases caused by [[trauma]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemangioma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid22701011">{{cite journal |vauthors=Alhajri K, Alhasan I, Alzerwi N, Abudaff N |title=Adrenal haemangioma |journal=BMJ Case Rep |volume=2011 |issue= |pages= |date=April 2011 |pmid=22701011 |pmc=3079485 |doi=10.1136/bcr.12.2010.3604 |url=}}</ref><ref name="pmid29560018">{{cite journal |vauthors=Iwamoto G, Shimokihara K, Kawahara T, Takamoto D, Yao M, Teranishi JI, Otani M, Uemura H |title=Adrenal Hemangioma: A Case of Retroperitoneal Tumor |journal=Case Rep Med |volume=2018 |issue= |pages=8796327 |date=2018 |pmid=29560018 |pmc=5836307 |doi=10.1155/2018/8796327 |url=}}</ref><ref name="pmid26600897">{{cite journal |vauthors=Tarchouli M, Boudhas A, Ratbi MB, Essarghini M, Njoumi N, Sair K, Zentar A |title=Giant adrenal hemangioma: Unusual cause of huge abdominal mass |journal=Can Urol Assoc J |volume=9 |issue=11-12 |pages=E834–6 |date=2015 |pmid=26600897 |pmc=4639440 |doi=10.5489/cuaj.2967 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Cortisol]] (rare)
* [[Aldosterone]] (rare)
* [[Androgens]] (rare)
|
* [[Abdominal]] [[mass]] & discomfort
* [[Nausea]] & [[vomiting]]
* Back [[pain]]
* [[Hypovolemic shock]] ([[hemorrhage]])
* [[Symptoms]] of [[hormonal]] excess (very rare)
|
* [[Abdominal]] [[mass]]
* [[Hypovolemic shock]] ([[hemorrhage]])
* [[Symptoms]] of [[hormonal]] excess (very rare)
|
* N/L
* [[Anemia]] ([[hemorrhage]])
* ↑ [[Serum]] and [[urinary]] [[Adrenal gland|adrenal hormones]] and [[metabolites]] (very rare)
|
* [[Histopathology]] is gold standard
* Most often [[cavernous]]
* Peripheral dilated [[vascular]] spaces
* Monostromatic [[endothelium]]
* Absence of [[atypia]]
* Central [[necrosis]]
* [[Calcification]]
* [[Hemorrhage]]
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[FDG]]-[[PET]] scan
* [[Endoscopic ultrasound]]
* Post-[[resection]] [[biopsy]] (if [[malignancy]] is suspected)
|
* [[Calcification]]
* [[Phleboliths]]
|
* [[Calcification]]
* [[Phleboliths]]
* Irregular peripheral enhancement
|
* N/A
|
* Hyperintensity (T2) hypointensity (T1)
* Peripheral spotty and centripetal enhancement
|
* Majority of the cases diagnosed incidentally
* Majority of the [[lesions]] are non-functional with [[female]] pre-dominance
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid28794358">{{cite journal |vauthors=Harada K, Kimura K, Iwamuro M, Terasaka T, Hanayama Y, Kondo E, Hayashi E, Yoshino T, Otsuka F |title=The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency |journal=Intern. Med. |volume=56 |issue=17 |pages=2261–2269 |date=September 2017 |pmid=28794358 |pmc=5635296 |doi=10.2169/internalmedicine.8216-16 |url=}}</ref><ref name="pmid27795295">{{cite journal |vauthors=Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM |title=Adrenal lymphoma: presentation, management and prognosis |journal=QJM |volume=110 |issue=2 |pages=103–109 |date=February 2017 |pmid=27795295 |doi=10.1093/qjmed/hcw174 |url=}}</ref><ref name="pmid29344029">{{cite journal |vauthors=Karimi F |title=Primary Adrenal Lymphoma Presenting with Adrenal Failure: A Case Report and Review of the Literature |journal=Int J Endocrinol Metab |volume=15 |issue=4 |pages=e12014 |date=October 2017 |pmid=29344029 |pmc=5750783 |doi=10.5812/ijem.12014 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* [[Fatigue]]
* Loss of [[appetite]]
* [[Weight loss]]
* [[Pigmentation]] of [[skin]]
* [[Flank]]/[[abdominal]] [[pain]]
* [[Fever]]
* [[Nausea]] & [[vomiting]]
|
* [[Hypotension]]
* [[Altered mental status]]
* [[Abdominal]]/[[flank]] [[mass]]
* [[Fever]]
* [[Weight loss]]
|
* ↑ [[ESR]]
* ↑ [[LDH]]
* ↑ [[Serum]] [[ACTH]]
* ↓ [[Hyponatremia]]
* Low early morning [[serum]] [[cortisol]] levels
* Low basal [[urinary]] [[cortisol]]
* ↓ [[Aldosterone]]
|
* [[Histopathology]] is gold standard
* Diffuse growth pattern with large [[cells]] ( 5× normal [[lymphocytes]]) resembling [[immunoblasts]]
* Extensive [[necrosis]]
* May resemble [[anaplastic]] large [[cell]] [[lymphoma]] or [[metastatic]] [[carcinoma]]
* Abundant [[T-cells]]
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[ACTH]] stimulation test
* [[CT]]-guided needle [[biopsy]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
* Heterogeneous [[mass]]
* [[Hemorrhages]]
|
* Heterogeneous [[mass]]
* [[Hemorrhages]]
* [[Necrosis]]
|
* N/A
|
* Enlarged [[retroperitoneal]] [[lymph nodes]]
* Low intensity (T1)
* High intensity (T2)
|
* May stain positive for:
** [[CD3]], [[CD19]], [[CD20]], [[CD22]]
** [[BCL6]] / [[CD10]]
** [[CD43]], [[CD45]]
** [[Immunoglobulin A|Surface Ig]]
** [[CD68]]
** [[CD79a]]
** [[LCA]]
** [[Pax genes|Pax 5]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystic Lymphangioma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid27011561">{{cite journal |vauthors=Michalopoulos N, Laskou S, Karayannopoulou G, Pavlidis L, Kanellos I |title=Adrenal Gland Lymphangiomas |journal=Indian J Surg |volume=77 |issue=Suppl 3 |pages=1334–42 |date=December 2015 |pmid=27011561 |pmc=4775622 |doi=10.1007/s12262-015-1206-y |url=}}</ref><ref name="pmid25197378">{{cite journal |vauthors=Zhao M, Gu Q, Li C, Yu J, Qi H |title=Cystic lymphangioma of adrenal gland: a clinicopathological study of 3 cases and review of literature |journal=Int J Clin Exp Pathol |volume=7 |issue=8 |pages=5051–6 |date=2014 |pmid=25197378 |pmc=4152068 |doi= |url=}}</ref><ref name="pmid25889625">{{cite journal |vauthors=Joliat GR, Melloul E, Djafarrian R, Schmidt S, Fontanella S, Yan P, Demartines N, Halkic N |title=Cystic lymphangioma of the adrenal gland: report of a case and review of the literature |journal=World J Surg Oncol |volume=13 |issue= |pages=58 |date=February 2015 |pmid=25889625 |pmc=4335415 |doi=10.1186/s12957-015-0490-0 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* Asymptomatic
* [[Flank]]/back/[[abdominal]] [[pain]]
* [[Abdominal]]/[[flank]] [[mass]]
* [[GI]] obstruction
|
* N/L
* Palpable [[mass]]
* [[Hypertension]]
* [[Fever]]
|
* N/L
|
* [[Histopathology]] is gold standard
* Cystic channels and spaces
* Flat [[endothelial cells]]
* Mature [[lymphoid]] aggregates
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[FDG]]-[[PET]] scan
* [[Aspiration]] & [[biopsy]]
|
* Well-demarcated
* [[Calcification]]
|
* Well-demarcated
* Low-density
* [[Calcification]]
|
* N/A
|
* T1 hypointense & T2 hyperintense
|
* Associated with [[Gorlin-Goltz syndrome]]
* Stains positive for [[CD31]], [[CD34]], and D2-40 and negative for [[cytokeratin]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Teratoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid29067922">{{cite journal |vauthors=Ramakant P, Rana C, Singh KR, Mishra A |title=Primary adrenal teratoma: An unusual tumor - Challenges in diagnosis and surgical management |journal=J Postgrad Med |volume=64 |issue=2 |pages=112–114 |date=2018 |pmid=29067922 |pmc=5954807 |doi=10.4103/jpgm.JPGM_588_16 |url=}}</ref><ref name="pmid26722254">{{cite journal |vauthors=Li S, Li H, Ji Z, Yan W, Zhang Y |title=Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults |journal=Oncol Lett |volume=10 |issue=5 |pages=2865–2870 |date=November 2015 |pmid=26722254 |pmc=4665718 |doi=10.3892/ol.2015.3701 |url=}}</ref><ref name="pmid30214733">{{cite journal |vauthors=Zhou L, Pan X, He T, Lai Y, Li W, Hu Y, Ni L, Yang S, Chen Y, Lai Y |title=Primary adrenal teratoma: A case series and review of the literature |journal=Mol Clin Oncol |volume=9 |issue=4 |pages=437–442 |date=October 2018 |pmid=30214733 |pmc=6125700 |doi=10.3892/mco.2018.1687 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* Asymptomatic
* [[Abdominal]]/back discomfort & [[pain]]
* [[Abdominal]] distension
* [[Lumbago]]
* [[Nausea]] & [[vomiting]]
* Local obstructive [[symptoms]]
|
* N/L
* [[Abdominal]] distension
* [[Abdominal]] [[mass]]
* [[Weight loss]]
* [[Urinary]] retention
* Lower extremity [[edema]]
* [[Peritoneal]] [[effusion]] or [[peritonitis]] (rupture)
|
* N/L
|
* [[Fibrous tissue]], [[adipose tissue]] and [[muscle fibers]]
* [[Stratified squamous epithelium]], [[hair]] shafts, [[fat cells]], [[GI]] and [[respiratory]] [[epithelium]]
* [[Necrosis]]
* [[Calcification]]
|
* Complete [[endocrine]] panel
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
* Post-resection [[biopsy]] (if [[malignancy]] is suspected)
|
* Heterogeneous
* Mixed echo ([[Ultrasonogram|U/S]])
|
* Heterogeneous
* Mixed density elements
* Egg-shell [[calcification]]
* Mild enhancement
|
* N/A
|
* Mild enhancement
* Mixed signals ([[MRI]])
|
* Derived from [[germ layers]]
* Majority are [[benign]], but about one forth of [[adrenal]] [[teratoma]] are [[malignant]] [[lesions]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Metastases]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid15541184">{{cite journal |vauthors=Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K |title=Large bilateral adrenal metastases in non-small cell lung cancer |journal=World J Surg Oncol |volume=2 |issue= |pages=37 |date=November 2004 |pmid=15541184 |pmc=535544 |doi=10.1186/1477-7819-2-37 |url=}}</ref><ref name="pmid15405683">{{cite journal |vauthors=ABRAMS HL, SPIRO R, GOLDSTEIN N |title=Metastases in carcinoma; analysis of 1000 autopsied cases |journal=Cancer |volume=3 |issue=1 |pages=74–85 |date=January 1950 |pmid=15405683 |doi= |url=}}</ref><ref name="pmid15554272">{{cite journal |vauthors=Gerber E, Dinlenc C, Wagner JR |title=Laparoscopic adrenalectomy for isolated adrenal metastasis |journal=JSLS |volume=8 |issue=4 |pages=314–9 |date=2004 |pmid=15554272 |pmc=3016821 |doi= |url=}}</ref><ref name="pmid9781426">{{cite journal |vauthors=Vaughan ED |title=Diagnosis and management of surgical adrenal disorders |journal=Int. J. Urol. |volume=5 |issue=5 |pages=401–17 |date=September 1998 |pmid=9781426 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* Related to the primary [[tumor]]
|
* Asymptomatic
* [[Adrenal insufficiency]]
* [[Abdominal]] [[mass]] & discomfort
* [[Symptoms]] due to primary [[tumor]] that may include:
** [[Lung cancer]]
** [[Breast cancer]]
** [[Gastric cancer]]
** [[Liver cancer]]
** [[Pancreatic cancer]]
** [[Renal cell carcinoma]]
** [[Melanoma]]
** [[Lymphoma]]
|
* Asymptomatic
* [[Adrenal insufficiency]]
* [[Abdominal]] [[mass]]
* [[Signs]] due to primary [[tumor]] that may include
** [[Lung cancer]]
** [[Breast cancer]]
** [[Gastric cancer]]
** [[Liver cancer]]
** [[Pancreatic cancer]]
** [[Renal cell carcinoma]]
** [[Melanoma]]
** [[Lymphoma]]
|
* Varies depending on the primary [[tumor]]
* N/L
* If [[adrenal insufficiency]]:
** [[Hyponatremia]]
** [[Hyperkalemia]]
** [[Hypoglycemia]]
** Low early morning [[serum]] [[cortisol]] levels
** Low basal [[urinary]] [[cortisol]]
** ↑ [[ACTH]]
** ↓ [[Aldosterone]]
** ↑ [[Plasma]] [[renin]]
|
* Single or multiple firm [[masses]]
* [[Hemorrhage]]
* [[Necrosis]]


</style><!--/custom_head--></head>
* [[Morphology]] similar to the primary [[tumor]]
* Compression and [[atrophy]] of adjacent [[adrenal]] [[tissue]]
|
* [[Blood]] and [[urine]] lab testing
* Complete [[endocrine]] panel
* [[Imaging]] of [[chest]], [[abdomen]], and [[pelvis]]
* [[Immunohistochemistry]]
* [[Endoscopy]]
* [[MRCP]] & [[ERCP]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
* [[Calcification]]
* [[Hemorrhage]]
|
* [[Calcification]]
* [[Hemorrhage]]
* Irregular peripheral enhancement
|
* N/A
|
* Low signal on T1-weighed [[MRI]] and high signal on T2-weighed [[MRI]]
OR
* Isointense on T1- and T2-weighed [[MRI]]
|
* [[Metastases]] more common than primary [[adrenal tumors]]
* [[Adrenal]] [[hemorrhage]] is the most serious [[complication]] and may present as [[adrenal crisis]] and/or [[shock]]
|}


<body class="reports " onload='IMS_Onload.run();'>
==References==
 
{{reflist|2}}
<!-- Blue Header -->
<!-- NCI, SEER, Search, Navigation -->
<a class="sr-only sr-only-focusable" href="#skipnav">Skip to Main Content</a>
 
<!-- HEADER -->
<header class="push" role="banner">
<div class="container">
    <div class="row">
        <div class="col-sm-8">
        <a class="seerLogo" href="/" title="Return Home">
        <img src="/i/seer.svg" alt="Surveillance, Epidemiology, and End Results Program" />
        </a>
            </div>
            <div class="col-sm-4 search">
<!-- Go to www.addthis.com/dashboard to customize your tools --> <div class="addthis_inline_share_toolbox"></div>
        <form action="/search" method="get" name="search" onSubmit="return searchCheck(this.q) && NCIAnalytics.SiteSearch(this);">
                        <label for="searchsite">Search SEER:</label>
                        <input id="searchsite" type="text" size="15" name="q" placeholder="Search SEER" />
                        <input type="image" src="/i/search_btn.png" class="greenBtn" alt="Search" />
                </form>
            </div>
        </div>
</div>
 
</header>
<!-- END HEADER -->
<div class="fixedtotop">
<div class="mobile-menu-bar navopen-menu-mobile"><button aria-expanded="false" type="button" class="open-panel nav-header menu-btn">Menu</button></div>
</div>
 
<div id="topnav">
 
    <!-- Global nav/utilit bar/language  -->
        <!-- BEGIN NAVIGATION -->
        <!-- Begin nav-search bar -->
        <div class="nav-search-bar gradient header container"><div id="nvcgSlMainNav" class="row">
 
<div class="slot-item first-SI">
<div class="navigation" role="application">
 
<nav id="mega-nav" role="navigation">
<ul class="menu nav-menu">
<li class="nav-item lvl-1 item-1 home">
<div class="nav-item-title">
<a href="/">Home</a>
</div><ul class="mobile-item">
      </ul>
</li>
<li class="nav-item lvl-1 has-children item-2 statistics">
<div class="nav-item-title">
<a href="/statistics/"><span>Cancer Statistics</span> <img src="/i/caret-down-sm-f.png" alt="" /></a>
</div>
<ul class="mobile-item">
<li class="lvl-2 has-children">
<div class="nav-item-title">
<a href="/statistics/reports.html">Reports on Cancer</a>
</div>
<ul class="mobile-item">
<li class="lvl-3">
<div class="nav-item-title">
<a href="/report_to_nation/">Annual Report to the Nation on the Status of Cancer</a>
</div>
</li>
<li class="lvl-3">
<div class="nav-item-title">
<a href="/statfacts/">Cancer Stat Facts</a>
</div>
</li>
<li class="lvl-3">
<div class="nav-item-title">
<a href="/csr/">Cancer Statistics Review</a>
</div>
</li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/statistics/resources.html">Understanding Statistics</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/statistics/videos/">Did You Know? Video Series</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/statistics/types.html">Defining Cancer Statistics</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/cgi-bin/glossary/glossary.pl">Glossary of Statistical Terms</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/statistics/interactive.html">Interactive Tools, Maps, &amp; Graphs</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/explorer/">SEER*Explorer</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/faststats/index.php">Fast Stats</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/canstat/">CanStat Animator</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/canques/">Cancer Query Systems</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/publications/">SEER Publications</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/pubsearch/">SEER Bibliography</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/publications/monographs.html">Monographs</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/cgi-bin/pubs/order1.pl?MONO,CSR,ABOUT,CODING,BOOK,CONV,">Publication Order Form</a>
</div></li>
</ul></li>
</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper">
<ul class="sub-nav-group"><li><a href="/statistics/reports.html" class="sub-nav-group-header">Reports on Cancer</a>
  <ul>
    <li><a href="/report_to_nation/">Annual Report to the Nation on the Status of Cancer</a></li>
    <li><a href="/statfacts/">Cancer Stat Facts</a></li>
    <li><a href="/csr/">Cancer Statistics Review</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/statistics/resources.html" class="sub-nav-group-header">Understanding Statistics</a>
  <ul>
    <li><a href="/statistics/videos/">Did You Know? Video Series</a></li>
    <li><a href="/statistics/types.html">Defining Cancer Statistics</a></li>
    <li><a href="/cgi-bin/glossary/glossary.pl">Glossary of Statistical Terms</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/statistics/interactive.html" class="sub-nav-group-header">Interactive Tools, Maps, &amp; Graphs</a>
  <ul>
    <li><a href="/explorer/">SEER*Explorer</a></li>
    <li><a href="/faststats/index.php">Fast Stats</a></li>
    <li><a href="/canstat/">CanStat Animator</a></li>
    <li><a href="/canques/">Cancer Query Systems</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/publications/" class="sub-nav-group-header">SEER Publications</a>
  <ul>
    <li><a href="/pubsearch/">SEER Bibliography</a></li>
    <li><a href="/publications/monographs.html">Monographs</a></li>
    <li><a href="/cgi-bin/pubs/order1.pl?MONO,CSR,ABOUT,CODING,BOOK,CONV,">Publication Order Form</a></li>
  </ul></li></ul>
</div></div>
</div></li>
<li class="nav-item lvl-1 has-children item-3 data-soft"><div class="nav-item-title">
<a href="/data-software/"><span>SEER Data &amp; Software</span> <img src="/i/caret-down-sm-f.png" alt="" /></a>
</div><ul class="mobile-item">
<li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/data/">SEER Incidence Database</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/data/options.html">Access Options</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/seertrack/data/request/">Request the Data</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/data/sample-dua.html">Sample Data Use Agreement</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/data-software/documentation/">Documentation for Data</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/data-software/documentation/seerstat/">SEER*Stat Database Details</a>
</div></li><li class="lvl-3">
  <div class="nav-item-title">
<a href="/analysis/">Variable and Recode Definitions</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/data-software/documentation/ascii-files.html">ASCII Data File Documentation</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/data-software/datasets.html">U.S. Datasets</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/mortality/">U.S. Mortality</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/popdata/">U.S. Populations</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/stdpopulations/">Standard Populations</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/data-software/linked_databases.html">SEER Linked Databases</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/data-software/software.html">Statistical Software</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/seerstat/">SEER*Stat</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/seerprep/">SEER*Prep</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/hdcalc/">Health Disparities Calculator</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/data-software/related.html">Analytic Software</a>
</div></li>
</ul></li>
</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper">
<ul class="sub-nav-group"><li><a href="/data/" class="sub-nav-group-header">SEER Incidence Database</a>
  <ul>
    <li><a href="/data/options.html">Access Options</a></li>
    <li><a href="/seertrack/data/request/">Request the Data</a></li>
    <li><a href="/data/sample-dua.html">Sample Data Use Agreement</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/data-software/documentation/" class="sub-nav-group-header">Documentation for Data</a>
  <ul>
    <li><a href="/data-software/documentation/seerstat/">SEER*Stat Database Details</a></li>
    <li><a href="/analysis/">Variables and Recode Definitions</a></li>
    <li><a href="/data-software/documentation/ascii-files.html">ASCII Data File Documentation</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/data-software/datasets.html" class="sub-nav-group-header">U.S. Datasets</a>
  <ul>
    <li><a href="/mortality/">U.S. Mortality</a></li>
    <li><a href="/popdata/">U.S. Populations</a></li>
    <li><a href="/stdpopulations/">Standard Populations</a></li>
    <li><a href="/data-software/linked_databases.html">SEER Linked Databases</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/data-software/software.html" class="sub-nav-group-header">Statistical Software</a>
  <ul>
    <li><a href="/seerstat/">SEER*Stat</a></li>
    <li><a href="/seerprep/">SEER*Prep</a></li>
    <li><a href="/hdcalc/">Health Disparities Calculator</a></li>
<li><a href="/data-software/related.html">Analytic Software</a></li>
  </ul></li></ul>
</div></div>
</div></li>
<li class="nav-item lvl-1 has-children item-4 registrars"><div class="nav-item-title">
<a href="/registrars/"><span>Registry Operations</span> <img src="/i/caret-down-sm-f.png" alt="" /></a>
</div><ul class="mobile-item">
<li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/registrars/guidelines.html">Reporting Guidelines</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/tools/codingmanuals/index.html">SEER Program Coding Manual</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/tools/heme/">Hematopoietic Project</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/tools/solidtumor/">2018 Solid Tumor Rules</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/registrars/tools-software.html">Tools &amp; Software</a>
</div>
<ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/seertools/glossary/">Glossary for Registrars</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/tools/seerrx/">SEER*Rx - Drug Database</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/seerabs/">SEER Abstracting Tool</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/seerdms/index.html">SEER Data Management System (SEER*DMS)</a>
</div>
</li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/registrars/qa.html">Questions &amp; Answers</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/registrars/contact.html">Ask a SEER Registrar</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/registrars/data-collection.html">Data Collection Answers</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/seerinquiry/index.php">SEER Inquiry System</a>
</div></li>
</ul></li><li class="lvl-2 has-children"><div class="nav-item-title">
<a href="/registrars/staging.html">Staging</a>
</div><ul class="mobile-item">
<li class="lvl-3"><div class="nav-item-title">
<a href="/tools/staging/rsa.html">Registrar Staging Assistant (SEER*RSA)</a>
</div></li><li class="lvl-3">
  <div class="nav-item-title">
<a href="/tools/ssm/">Summary Stage 2018</a>
</div></li><li class="lvl-3"><div class="nav-item-title">
<a href="/tools/staging/index.html">Staging Resources</a>
</div></li>
</ul></li><li class="lvl-2"><div class="nav-item-title">
<a href="/training">Training</a>
</div><ul class="mobile-item">
  <li class="lvl-3"><div class="nav-item-title"></div></li>
</ul></li>
</ul><div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
<div class="sub-nav-group-wrapper"><div class="sub-nav-group-subwrapper">
<ul class="sub-nav-group"><li><a href="/registrars/guidelines.html" class="sub-nav-group-header">Reporting Guidelines</a>
  <ul>
    <li><a href="/tools/codingmanuals/index.html">SEER Program Coding Manual</a></li>
    <li><a href="/tools/heme/">Hematopoietic Project</a></li>
    <li><a href="/tools/solidtumor/">2018 Solid Tumor Rules</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/registrars/tools-software.html" class="sub-nav-group-header">Tools &amp; Software</a>
  <ul>
    <li><a href="/seertools/glossary/">Glossary for Registrars</a></li>
    <li><a href="/tools/seerrx/">SEER*Rx - Drug Database</a></li>
    <li><a href="/seerabs/">SEER Abstracting Tool</a></li>
<li><a href="/seerdms/index.html">SEER Data Management System (SEER*DMS)</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/registrars/qa.html" class="sub-nav-group-header">Questions &amp; Answers</a>
  <ul>
    <li><a href="/registrars/contact.html">Ask a SEER Registrar</a></li>
    <li><a href="/registrars/data-collection.html">Data Collection Answers</a></li>
    <li><a href="/seerinquiry/index.php">SEER Inquiry System</a></li>
  </ul></li></ul>
<ul class="sub-nav-group"><li><a href="/registrars/staging.html" class="sub-nav-group-header">Staging</a>
  <ul>
    <li><a href="/tools/staging/rsa.html">Registrar Staging Assistant (SEER*RSA)</a></li>
    <li><a href="/tools/ssm/">Summary Stage 2018</a></li>
                                <li><a href="/tools/staging/index.html">Staging Resources</a></li>
  </ul></li><br />
  <li><a href="/training/" class="sub-nav-group-header">Training</a></li>
</ul>
</div></div>
</div></li>
<li class="nav-item lvl-1 item-5 news"><div class="nav-item-title">
<a href="/news/">News</a>
</div><ul class="mobile-item">
      </ul></li>
<li class="nav-item lvl-1 item-6 about"><div class="nav-item-title">
<a href="/about/">About</a>
</div><ul class="mobile-item">
      </ul></li>
 
</ul>
</nav>
</div>
</div>
 
<div class="slot-item last-SI"></div>
</div></div>
        <!-- End nav-search bar -->
        <!-- END NAVIGATION -->
    <!-- END Global nav/utility bar/language -->
 
</div>
<!-- End topnav -->
 
 
<!-- White Section -->
<div class="section">
<div class="highlighted">
    <!-- Crumbs -->
        <div class="container"> 
<button class="togLeftNav button" data-toggle="modal" data-target="#leftNav"><span>Section Menu</span></button>
            <div class="crumbs"><a class="home" href="/"><img src="/i/icn_home.png" alt="Return Home" /> Home</a>  <img class="arrow" src="/i/crumb_arrow.png" alt=""/> <a href="/statistics/">Cancer Statistics</a> <img class="arrow" src="/i/crumb_arrow.png" alt=""/> <a href="/statistics/reports.html">Reports on Cancer</a> <img class="arrow" src="/i/crumb_arrow.png" alt=""/> <a href="/statfacts/">Cancer Stat Facts</a> <img class="arrow" src="/i/crumb_arrow.png" alt=""/> <a href="/statfacts/more.html">More Cancer Types</a> <img class="arrow" src="/i/crumb_arrow.png" alt=""/> Myeloma</div>            <h1><!--body_title-->Cancer Stat Facts:  Myeloma<!--/body_title--></h1>
        </div>   
    </div>
    <div class="container body"><img src="/i/left-body.png" alt="" class="bg-front">
    <div class="row">
    <!-- Smaller, Aside Column -->
        <div class="col-md-3">
         
<div class="leftNav-wrap">
            <nav class="subNav leftNav" aria-label="Reports on Cancer">
<strong><a href="/statistics/reports.html">Reports on Cancer</a></strong>
<ul>
<li><a href="/report_to_nation/">Annual Report to the Nation</a></li>
<li><a href="/statfacts/">Cancer Stat Facts</a>
<ul>
<li><a href="/statfacts/html/common.html">Common Cancer Sites</a></li>
<li><a href="/statfacts/html/disparities.html">Cancer Disparities</a></li>
<li><a href="/statfacts/html/urinb.html">Bladder</a></li>
<li><a href="/statfacts/html/breast.html">Breast (Female)</a></li>
<li><a href="/statfacts/html/colorect.html">Colon and Rectum</a></li>               
<li><a href="/statfacts/html/kidrp.html">Kidney and Renal Pelvis</a></li>
<li><a href="/statfacts/html/leuks.html">Leukemia</a></li>
<li><a href="/statfacts/html/lungb.html">Lung and Bronchus</a></li>
<li><a href="/statfacts/html/melan.html">Melanoma of the Skin</a></li>
<li><a href="/statfacts/html/nhl.html">Non-Hodgkin Lymphoma</a> </li>
<li><a href="/statfacts/html/pancreas.html">Pancreas</a></li>
<li><a href="/statfacts/html/prost.html">Prostate</a></li>
<li><a href="/statfacts/html/thyro.html">Thyroid</a></li>
<li><a href="/statfacts/html/corp.html">Uterus</a></li>
<li><a class="active" href="/statfacts/more.html">More Cancer Types</a></li>
</ul>
</li>
<li><a href="/csr/1975_2015/">Cancer Statistics Review, 1975-2015</a>
<ul>
<li><a href="/csr/1975_2015/browse_csr.php">Browse the Tables and Figures</a></li>
<li><a href="/csr/1975_2015/sections.html">Access CSR Contents in PDF</a></li>
<li><a href="/cgi-bin/csr/1975_2015/search.pl">Generate Custom Reports</a></li>
<li><a href="/csr/1975_2015/revisions.html">Revision History</a></li>
<li><a href="/csr/previous.html">Archive</a></li>
</ul>
</li>       
</ul>
</nav> </div>
        </div>
        <!-- Main Content Column -->
        <main class="col-md-9" id="content" role="main">         
            <a name="skipnav" id="skipnav" tabindex="-1"></a>
            <!--body_content--><div class="factSheet">
<div class="superTog">
<a class="expandAll" href="#" title="Expand All Stat Fact Sections">Expand All</a>
<a class="collapseAll" href="#" title="Collapse All Fact Sheet Sections">Collapse All</a>
</div>
 
<h2 class="tog-control default-open">Statistics at a Glance</h2>
<div class="tog-content">
        <h3>At a Glance</h3>
        <div class="glance-factSheet">       
<div class="row">
<div class="col-sm-7">
<div class="glanceBox new">
<p><span>Estimated New Cases in 2018</span> <span>30,770</span></p>
<p><span>% of All New Cancer Cases</span> <span>1.8%</span></p>
</div>
 
<div class="glanceBox death">
<p><span>Estimated Deaths in 2018</span> <span>12,770</span></p>
<p><span>% of All Cancer Deaths</span> <span>2.1%</span></p>
</div>
</div>
<div class="col-sm-4 col-sm-offset-1">
<div class="statBox text-center">
<p>Percent Surviving<br/>5 Years</p>
<strong>50.7%</strong>
<span>2008-2014</span>
</div>
</div>
</div>
 
<!-- Default Display of Data -->
<div class="defaultData showData-table-1">
<div class="scrapeTable">
<table id="scrapeTable_01">
<thead>
<tr>
<th rowspan="2" scope="col">Year</th>
<th colspan="2" scope="col">New Cases - SEER 9 </th>
<th colspan="2" scope="col">New Cases - SEER 13</th>
<th colspan="2" scope="col">Deaths - U.S.</th>
<th colspan="2"scope="col">Percent Surviving 5 Years - SEER 9</th>
</tr>
<tr>
<th>Observed</th>
<th>Modeled Trend</th>
<th>Observed</th>
<th>Modeled Trend</th>
<th>Observed</th>
<th>Modeled Trend</th>
<th>Observed</th>
<th>Modeled Trend</th>
</tr>
</thead>
<tbody>     
<tr>
<td>1975</td>
<td>4.91</td>
<td>4.87</td>               
<td>-</td>
<td>-</td>               
<td>2.94</td>
<td>3.03</td>
<td>26.54%</td>
<td>25.02%</td>
</tr>     
<tr>
<td>1976</td>
<td>5.02</td>
<td>4.92</td>               
<td>-</td>
<td>-</td>               
<td>3.10</td>
<td>3.08</td>
<td>23.65%</td>
<td>25.36%</td>
</tr>     
<tr>
<td>1977</td>
<td>5.06</td>
<td>4.96</td>               
<td>-</td>
<td>-</td>               
<td>3.13</td>
<td>3.13</td>
<td>24.17%</td>
<td>25.71%</td>
</tr>     
<tr>
<td>1978</td>
<td>4.75</td>
<td>5.00</td>               
<td>-</td>
<td>-</td>               
<td>3.17</td>
<td>3.17</td>
<td>26.93%</td>
<td>26.06%</td>
</tr>     
<tr>
<td>1979</td>
<td>4.88</td>
<td>5.05</td>               
<td>-</td>
<td>-</td>               
<td>3.26</td>
<td>3.22</td>
<td>25.52%</td>
<td>26.42%</td>
</tr>     
<tr>
<td>1980</td>
<td>4.79</td>
<td>5.09</td>               
<td>-</td>
<td>-</td>               
<td>3.27</td>
<td>3.27</td>
<td>26.00%</td>
<td>26.77%</td>
</tr>     
<tr>
<td>1981</td>
<td>5.03</td>
<td>5.14</td>               
<td>-</td>
<td>-</td>               
<td>3.29</td>
<td>3.32</td>
<td>27.02%</td>
<td>27.12%</td>
</tr>     
<tr>
<td>1982</td>
<td>5.29</td>
<td>5.18</td>               
<td>-</td>
<td>-</td>               
<td>3.38</td>
<td>3.37</td>
<td>28.45%</td>
<td>27.48%</td>
</tr>     
<tr>
<td>1983</td>
<td>5.31</td>
<td>5.23</td>               
<td>-</td>
<td>-</td>               
<td>3.44</td>
<td>3.42</td>
<td>27.53%</td>
<td>27.84%</td>
</tr>     
<tr>
<td>1984</td>
<td>5.41</td>
<td>5.27</td>               
<td>-</td>
<td>-</td>               
<td>3.47</td>
<td>3.47</td>
<td>26.33%</td>
<td>28.19%</td>
</tr>     
<tr>
<td>1985</td>
<td>5.21</td>
<td>5.32</td>               
<td>-</td>
<td>-</td>               
<td>3.58</td>
<td>3.52</td>
<td>27.36%</td>
<td>28.55%</td>
</tr>     
<tr>
<td>1986</td>
<td>5.34</td>
<td>5.37</td>               
<td>-</td>
<td>-</td>               
<td>3.61</td>
<td>3.57</td>
<td>28.76%</td>
<td>28.91%</td>
</tr>     
<tr>
<td>1987</td>
<td>5.93</td>
<td>5.41</td>               
<td>-</td>
<td>-</td>               
<td>3.61</td>
<td>3.62</td>
<td>27.56%</td>
<td>29.27%</td>
</tr>     
<tr>
<td>1988</td>
<td>5.33</td>
<td>5.46</td>               
<td>-</td>
<td>-</td>               
<td>3.63</td>
<td>3.68</td>
<td>28.98%</td>
<td>29.63%</td>
</tr>     
<tr>
<td>1989</td>
<td>5.44</td>
<td>5.51</td>               
<td>-</td>
<td>-</td>               
<td>3.70</td>
<td>3.73</td>
<td>25.70%</td>
<td>29.99%</td>
</tr>     
<tr>
<td>1990</td>
<td>5.67</td>
<td>5.56</td>               
<td>-</td>
<td>-</td>               
<td>3.80</td>
<td>3.79</td>
<td>29.98%</td>
<td>30.36%</td>
</tr>     
<tr>
<td>1991</td>
<td>6.05</td>
<td>5.61</td>               
<td>-</td>
<td>-</td>               
<td>3.87</td>
<td>3.85</td>
<td>31.13%</td>
<td>30.72%</td>
</tr>     
<tr>
<td>1992</td>
<td>5.96</td>
<td>5.65</td>               
<td>5.81</td>
<td>5.72</td>               
<td>3.80</td>
<td>3.90</td>
<td>27.28%</td>
<td>31.08%</td>
</tr>     
<tr>
<td>1993</td>
<td>5.60</td>
<td>5.70</td>               
<td>5.68</td>
<td>5.74</td>               
<td>3.96</td>
<td>3.96</td>
<td>31.22%</td>
<td>31.45%</td>
</tr>     
<tr>
<td>1994</td>
<td>5.74</td>
<td>5.75</td>               
<td>5.71</td>
<td>5.76</td>               
<td>3.97</td>
<td>3.94</td>
<td>30.88%</td>
<td>31.81%</td>
</tr>     
<tr>
<td>1995</td>
<td>5.76</td>
<td>5.80</td>               
<td>5.61</td>
<td>5.78</td>               
<td>3.98</td>
<td>3.92</td>
<td>33.50%</td>
<td>32.18%</td>
</tr>     
<tr>
<td>1996</td>
<td>5.84</td>
<td>5.86</td>               
<td>5.92</td>
<td>5.80</td>               
<td>3.91</td>
<td>3.90</td>
<td>32.11%</td>
<td>32.55%</td>
</tr>     
<tr>
<td>1997</td>
<td>6.15</td>
<td>5.91</td>               
<td>6.06</td>
<td>5.83</td>               
<td>3.90</td>
<td>3.88</td>
<td>31.60%</td>
<td>32.91%</td>
</tr>     
<tr>
<td>1998</td>
<td>5.98</td>
<td>5.96</td>               
<td>5.79</td>
<td>5.85</td>               
<td>3.83</td>
<td>3.87</td>
<td>34.56%</td>
<td>33.28%</td>
</tr>     
<tr>
<td>1999</td>
<td>5.65</td>
<td>6.01</td>               
<td>5.68</td>
<td>5.87</td>               
<td>3.84</td>
<td>3.85</td>
<td>31.69%</td>
<td>33.65%</td>
</tr>     
<tr>
<td>2000</td>
<td>6.16</td>
<td>6.06</td>               
<td>6.00</td>
<td>5.89</td>               
<td>3.83</td>
<td>3.83</td>
<td>34.91%</td>
<td>35.48%</td>
</tr>     
<tr>
<td>2001</td>
<td>5.95</td>
<td>6.12</td>               
<td>5.81</td>
<td>5.91</td>               
<td>3.80</td>
<td>3.81</td>
<td>37.85%</td>
<td>37.31%</td>
</tr>     
<tr>
<td>2002</td>
<td>6.07</td>
<td>6.17</td>               
<td>5.88</td>
<td>5.93</td>               
<td>3.81</td>
<td>3.79</td>
<td>40.28%</td>
<td>39.14%</td>
</tr>     
<tr>
<td>2003</td>
<td>5.93</td>
<td>6.23</td>               
<td>5.98</td>
<td>5.95</td>               
<td>3.72</td>
<td>3.71</td>
<td>42.34%</td>
<td>40.97%</td>
</tr>     
<tr>
<td>2004</td>
<td>5.99</td>
<td>6.28</td>               
<td>6.07</td>
<td>5.97</td>               
<td>3.58</td>
<td>3.64</td>
<td>45.78%</td>
<td>42.79%</td>
</tr>     
<tr>
<td>2005</td>
<td>6.27</td>
<td>6.34</td>               
<td>6.17</td>
<td>5.99</td>               
<td>3.58</td>
<td>3.57</td>
<td>47.00%</td>
<td>44.59%</td>
</tr>     
<tr>
<td>2006</td>
<td>6.03</td>
<td>6.39</td>               
<td>5.91</td>
<td>6.02</td>               
<td>3.50</td>
<td>3.49</td>
<td>46.66%</td>
<td>46.38%</td>
</tr>     
<tr>
<td>2007</td>
<td>6.13</td>
<td>6.45</td>               
<td>5.94</td>
<td>6.04</td>               
<td>3.49</td>
<td>3.42</td>
<td>46.70%</td>
<td>48.15%</td>
</tr>     
<tr>
<td>2008</td>
<td>6.46</td>
<td>6.50</td>               
<td>6.28</td>
<td>6.26</td>               
<td>3.33</td>
<td>3.35</td>
<td>50.59%</td>
<td>49.89%</td>
</tr>     
<tr>
<td>2009</td>
<td>6.65</td>
<td>6.56</td>               
<td>6.49</td>
<td>6.49</td>               
<td>3.29</td>
<td>3.35</td>
<td>53.15%</td>
<td>51.61%</td>
</tr>     
<tr>
<td>2010</td>
<td>6.83</td>
<td>6.62</td>               
<td>6.69</td>
<td>6.72</td>               
<td>3.32</td>
<td>3.35</td>
<td>53.24%</td>
<td>51.69%</td>
</tr>     
<tr>
<td>2011</td>
<td>7.05</td>
<td>6.68</td>               
<td>6.73</td>
<td>6.68</td>               
<td>3.38</td>
<td>3.34</td>
<td>-</td>
<td>51.78%</td>
</tr>     
<tr>
<td>2012</td>
<td>6.80</td>
<td>6.74</td>               
<td>6.62</td>
<td>6.64</td>               
<td>3.40</td>
<td>3.34</td>
<td>-</td>
<td>51.87%</td>
</tr>     
<tr>
<td>2013</td>
<td>6.99</td>
<td>6.79</td>               
<td>6.65</td>
<td>6.60</td>               
<td>3.32</td>
<td>3.33</td>
<td>-</td>
<td>51.96%</td>
</tr>     
<tr>
<td>2014</td>
<td>6.72</td>
<td>6.85</td>               
<td>6.45</td>
<td>6.55</td>               
<td>3.34</td>
<td>3.33</td>
<td>-</td>
<td>52.05%</td>
</tr>     
<tr>
<td>2015</td>
<td>7.04</td>
<td>6.91</td>               
<td>6.56</td>
<td>6.51</td>               
<td>3.30</td>
<td>3.33</td>
<td>-</td>
<td>52.14%</td>
</tr>
</tbody>
</table>
</div>
</div>
<!----------------------------->
 
<!-- Use Default Display Data to Generate... -->
<div class="svgEnhance cf" aria-hidden="true">
<div class="svg-wrap default-glance"> 
<div id="svg-graph-01-wrapper">
  <svg id="svg-graph-01" class="thick-lines" viewBox="0 0 805 300" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
<div id="legend_svg-graph-01" class="legend-inline"></div>
</div>
<!--------------------------------------------->
<p class="footnote">Modeled trend lines were calculated from the underlying rates using the <a href="https://surveillance.cancer.gov/joinpoint/">Joinpoint Trend Analysis Software.</a></p>
 
<!-- Hide this one from AT, they access the table above -->
<a href="#" class="showData-btn-1" data-toggle="modal" data-target="#showData1" aria-hidden="true">View Data Table</a>
        </div>
        <hr/>
       
      <p><strong>Number of New Cases and Deaths per 100,000:</strong> The number of new cases of myeloma was 6.7 per 100,000 men and women per year. The number of deaths was 3.3 per 100,000 men and women per year. These rates are age-adjusted and based on 2011-2015 cases and deaths.</p>
        <p><strong>Lifetime Risk of Developing Cancer</strong>: Approximately 0.8 percent of men and women will be diagnosed with myeloma at some point during their lifetime, based on 2013-2015 data.</p>     
        <p><strong>Prevalence of This Cancer</strong>: In 2015, there were an estimated 124,733 people living with myeloma in the United States.</p> 
    </div>
   
    <h2 class="tog-control">Survival Statistics</h2>               
    <div class="tog-content">
        <h3>How Many People Survive 5 Years Or More after Being Diagnosed with Myeloma?</h3>
        <p><a href="https://surveillance.cancer.gov/survival/measures.html">Relative survival</a> statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.</p>
       
        <div class="statWrap people-factSheet">
            <div class="top-statWrap">
            <div class="row">
<div class="col-lg-7 col-lg-offset-1 col-sm-8 text-center">
<img src="images/survival_people_charts/Surv_Chart_50_7_Percent_Survive.png" alt="50.7%" />
</div>
<div class="col-lg-3 col-sm-4">
<div class="statBox text-center">
<p>Percent Surviving<br/>5 Years</p>
<strong>50.7%</strong>
</div>
</div>
</div>
            </div>
            <p class="footnote">Based on data from SEER 18 2008-2014. Gray figures represent those who have died from myeloma. Green figures represent those who have survived 5 years or more.</p>
        </div>
 
<p><strong>Additional Information</strong></p>
<ul>
<li><a href="https://seer.cancer.gov/statistics/types/survival.html">More about 5-year survival rates</a></li>
</ul>
 
<h3>Survival by Stage</h3>
<p>Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. In general, if the cancer is found only in the part of the body where it started it is <em>localized</em> (sometimes referred to as stage 1). If it has spread to a different part of the body, the stage is <em>regional</em> or <em>distant</em>. The earlier myeloma is caught, the better chance a person has of surviving five years after being diagnosed. For myeloma, 5.0% are diagnosed at the local stage. The 5-year survival for localized myeloma is 72.0%.</p>
<div class="statWrap survival-factSheet">
<strong class="title">Percent of Cases &amp; 5-Year Relative Survival by Stage at Diagnosis: Myeloma</strong>
<div class="top-statWrap">
   
    <!-- Default Display of Data -->
    <!-- This Data Table should create two SVGs. The first column, percent of cases, should be a pie chart. The second column, 5-year relative survival should be a bar chart. There are times when this table could have a 5th row for In-Situ. -->
<div class="defaultData">
<div class="scrapeTable">
<table id="scrapeTable_02">
<thead>
<tr>
<th scope="col">Stage</th>
<th scope="col">Percent of Cases</th>
<th scope="col">5-Year Relative Survival</th>
</tr>
</thead>
<tbody>
<tr>
<th><strong>Localized</strong><br/> Confined to Primary Site</th>
<td>5%</td>
<td>72.0%</td>
</tr>
<tr>
<th><strong>Regional</strong><br/> Spread to Regional Lymph Nodes</th>
<td>0%</td>
<td>0.0%</td>
</tr>
<tr>
<th><strong>Distant</strong><br/> Cancer has Metastasized</th>
<td>95%</td>
<td>49.6%</td>
</tr>
<tr>
<th><strong>Unknown</strong><br/> Unstaged</th>
<td>0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</div>
</div>
    <!---------------------------->
   
<!-- Use Default Display Data to Generate... -->
<!-- The Pie Chart with Legend -->
<div class="svgEnhance cf" aria-hidden="true">
<div class="whiteBox">
<div class="text-center"><strong>Percent of Cases by Stage</strong></div>
<div class="row">
<div class="col-lg-6 col-lg-offset-1 col-sm-7">
<div class="svg-wrap default-pie">
<div id="svg-graph-02-wrapper">
  <svg id="svg-graph-02" viewBox="0 0 350 350" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
</div>
<div class="col-sm-5">
<ul>
<li><img src="/i/factsheets/legend-local.gif" alt="" /><strong>Localized (5%)</strong><br/>Confined to Primary Site</li>
<li><img src="/i/factsheets/legend-regional.gif" alt="" /><strong>Regional (0%)</strong><br/>Spread to Regional Lymph Nodes</li>
<li><img src="/i/factsheets/legend-distant.gif" alt="" /><strong>Distant (95%)</strong><br/>Cancer Has Metastasized</li>
<li><img src="/i/factsheets/legend-unknown.gif" alt="" /><strong>Unknown (0%)</strong><br/>Unstaged</li>
</ul>
</div>
</div>
</div>
</div>
<!--------------------------------------------->
 
 
<!-- Use Default Display Data to Generate... -->
<!-- The Bar Chart -->
<div class="svgEnhance cf" aria-hidden="true">
<div class="whiteBox">
<div class="text-center"><strong>5-Year Relative Survival</strong></div>
<div class="row">
<div class="col-sm-8 col-sm-offset-2">
<div class="svg-wrap default-survival">
<div id="svg-graph-03-wrapper">
  <svg id="svg-graph-03" viewBox="0 0 400 250" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
</div>
</div>
</div>
</div>
<!--------------------------------------------->
</div>
<p class="footnote">SEER 18 2008-2014, All Races, Both Sexes by SEER Summary Stage 2000</p>
  </div>
             
        <p><strong>Additional Information</strong></p>
        <ul>
            <li><a href="https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/all">More about myeloma staging</a></li>
        </ul>
    </div> 
 
    <h2 class="tog-control">Number of New Cases and Deaths</h2>
    <div class="tog-content">   
        <h3>How Common Is This Cancer?</h3>
<p>Compared to other cancers, myeloma is relatively rare.</p>       
        <div class="statWrap common-factSheet">
            <div class="top-statWrap">
            <div class="row">
<div class="col-md-8">
<div class="table-responsive">
<table class="common">
<thead>
<tr>
<th scope="col" class="rank"><span class="sr-only">Rank</span></th>
<th scope="col">Common Types of Cancer</th>
<th scope="col" class="bordered">Estimated New<br/>Cases 2018</th>
<th scope="col">Estimated<br/>Deaths 2018</th>
</tr>
</thead>
<tbody>                       
<tr>                           
<td class="rank">1.</td>                               
<td>Breast Cancer (Female)</td>                             
<td>266,120</td>
<td>40,920</td>
</tr>                       
<tr>                           
<td class="rank">2.</td>                             
<td>Lung and Bronchus Cancer</td>                             
<td>234,030</td>
<td>154,050</td>
</tr>                       
<tr>                           
<td class="rank">3.</td>                             
<td>Prostate Cancer</td>                             
<td>164,690</td>
<td>29,430</td>
</tr>                       
<tr>                           
<td class="rank">4.</td>                             
<td>Colorectal Cancer</td>                             
<td>140,250</td>
<td>50,630</td>
</tr>                       
<tr>                           
<td class="rank">5.</td>                             
<td>Melanoma of the Skin</td>                             
<td>91,270</td>
<td>9,320</td>
</tr>                       
<tr>                           
<td class="rank">6.</td>                             
<td>Bladder Cancer</td>                             
<td>81,190</td>
<td>17,240</td>
</tr>                       
<tr>                           
<td class="rank">7.</td>                             
<td>Non-Hodgkin Lymphoma</td>                             
<td>74,680</td>
<td>19,910</td>
</tr>                       
<tr>                           
<td class="rank">8.</td>                             
<td>Kidney and Renal Pelvis Cancer</td>                             
<td>65,340</td>
<td>14,970</td>
</tr>                       
<tr>                           
<td class="rank">9.</td>                             
<td>Uterine Cancer</td>                             
<td>63,230</td>
<td>11,350</td>
</tr>                       
<tr>                           
<td class="rank">10.</td>                             
<td>Leukemia</td>                             
<td>60,300</td>
<td>24,370</td>
</tr>
<tr>
                                <td class="rank"></td>
                                <td>-</td>
                                <td>-</td>
                                <td>-</td>
</tr>
<tr class="selected">
<td class="rank">14.</td>
<td> Myeloma</td>
<td>30,770</td>
<td>12,770</td>
</tr>                   
</tbody>
</table>
</div>
</div>               
<div class="col-md-4 col-md-offset-0 col-sm-8 col-sm-offset-2 col-xs-10 col-xs-offset-1 text-center">
<p class="asideText">Myeloma represents 1.8% of all new cancer cases in the U.S.</p>
<img src="images/est_cases_deaths/How_common_pie_1_8.png" alt="" />
<p id="pie-percent"><strong>1.8%<br/></strong></p>
</div>
</div>
            </div>
        </div>
        <p>In 2018, it is estimated that there will be 30,770 new cases of myeloma and an estimated 12,770 people will die of this disease. </p> 
 
        <h3>Who Gets This Cancer?</h3>
        <p>Although a rare disease, myeloma is more common in men than women and among individuals of African American descent.  Risk is higher among those with a history of monoclonal gammopathy of undetermined significance (MGUS). The number of new cases of myeloma was 6.7 per 100,000 men and women per year based on 2011-2015 cases.</p>
 
        <div class="statWrap bar-factSheet">
            <strong class="title">Number of New Cases per 100,000 Persons by Race/Ethnicity &amp; Sex: Myeloma </strong>
            <div class="top-statWrap cf">
             
                <!-- Default Display of Data -->
<div class="defaultData cf tabletShow">
<div class="scrapeTable halfSize">
<h5>Males</h5>
<table id="scrapeTable_04">
<tr>
<th scope="row" width="60%"><strong>All Races</strong></th>
<td>8.4</td>
</tr>
<tr>
<th scope="row"><strong>White</strong></th>
<td>7.9</td>
</tr>
<tr>
<th scope="row"><strong>Black</strong></th>
<td>15.9</td>
</tr>
<tr>
<th scope="row"><strong>Asian/Pacific Islander</strong></th>
<td>4.9</td>
</tr>
<tr>
<th scope="row"><strong>American Indian/Alaska Native</strong></th>
<td>6.2</td>
</tr>
<tr>
<th scope="row"><strong>Hispanic</strong></th>
<td>7.6</td>
</tr>
<tr>
<th scope="row"><strong>Non-Hispanic</strong></th>
<td>8.5</td>
</tr>
</table>
</div>
<div class="scrapeTable halfSize">
<h5>Females</h5>
<table id="scrapeTable_05">
<tr>
<th scope="row" width="60%"><strong>All Races</strong></th>
<td>5.3</td>
</tr>
<tr>
<th scope="row"><strong>White</strong></th>
<td>4.7</td>
</tr>
<tr>
<th scope="row"><strong>Black</strong></th>
<td>11.6</td>
</tr>
<tr>
<th scope="row"><strong>Asian/Pacific Islander</strong></th>
<td>3.1</td>
</tr>
<tr>
<th scope="row"><strong>American Indian/Alaska Native</strong></th>
<td>5.5</td>
</tr>
<tr>
<th scope="row"><strong>Hispanic</strong></th>
<td>5.0</td>
</tr>
<tr>
<th scope="row"><strong>Non-Hispanic</strong></th>
<td>5.4</td>
</tr>
</table>
</div>
</div>
<!--------------------------->
             
                <!-- Use Default Display Data to Generate... -->
<div class="svgEnhance cf tabletHide" aria-hidden="true">
<!-- NEW SVG HERE INSTEAD OF OLD METHOD -->
<div class="topcap"><img class="male" src="/i/factsheets/bargraph_male.jpg" alt="Males" /><img class="female" src="/i/factsheets/bargraph_female.jpg" alt="Females" /></div>
<ul id="eagleChart-01">
<li><span id="ec01m01"><div class="svg-wrap default-bar"><svg id="ec01m01-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">All Races</span><span id="ec01f01"><div class="svg-wrap default-bar"><svg id="ec01f01-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec01m02"><div class="svg-wrap default-bar"><svg id="ec01m02-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">White</span><span id="ec01f02"><div class="svg-wrap default-bar"><svg id="ec01f02-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec01m03"><div class="svg-wrap default-bar"><svg id="ec01m03-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Black</span><span id="ec01f03"><div class="svg-wrap default-bar"><svg id="ec01f03-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec01m04"><div class="svg-wrap default-bar"><svg id="ec01m04-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Asian /<br/>Pacific Islander</span><span id="ec01f04"><div class="svg-wrap default-bar"><svg id="ec01f04-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec01m05"><div class="svg-wrap default-bar"><svg id="ec01m05-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">American Indian /<br/>Alaska Native</span><span id="ec01f05"><div class="svg-wrap default-bar"><svg id="ec01f05-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec01m06"><div class="svg-wrap default-bar"><svg id="ec01m06-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Hispanic</span><span id="ec01f06"><div class="svg-wrap default-bar"><svg id="ec01f06-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li class="last"><span id="ec01m07"><div class="svg-wrap default-bar"><svg id="ec01m07-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Non-Hispanic</span><span id="ec01f07"><div class="svg-wrap default-bar"><svg id="ec01f07-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>                 
</ul>
<div class="bottomcap"></div>
</div>
                <!--------------------------------------------->
               
            </div>
            <p class="footnote">SEER 18 2011-2015, Age-Adjusted</p>
</div>
 
        <div class="statWrap whogets-factSheet">
            <strong class="title">Percent of New Cases by Age Group: Myeloma</strong>
            <div class="top-statWrap">
            <div class="row"> 
<div class="col-md-8">
 
<!-- Default Display of Data -->
<div class="defaultData tinyShow">
<div class="scrapeTable">
<table id="scrapeTable_03">
<thead>
<tr>
<th scope="col">Age Range</th>
<th scope="col">Percent of New Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20</td>
<td>0.0%</td>
</tr>
<tr>
<td>20-34</td>
<td>0.5%</td>
</tr>
<tr>
<td>35-44</td>
<td>2.8%</td>
</tr>
<tr>
<td>45-54</td>
<td>10.9%</td>
</tr>
<tr>
<td>55-64</td>
<td>23.2%</td>
</tr>
<tr>
<td>65-74</td>
<td>29.8%</td>
</tr>
<tr>
<td>75-84</td>
<td>23.7%</td>
</tr>
<tr>
<td>&gt;84</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</div>
</div>
<!-------------------------->
<!-- Use Default Display Data to Generate... -->
    <div class="svgEnhance cf tinyHide" aria-hidden="true">
<div class="whiteBox">
<div class="svg-wrap default-new">
<div id="svg-graph-04-wrapper">
  <svg id="svg-graph-04" viewBox="0 0 400 275" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
</div>
</div>
<!--------------------------------------------->
</div>
<div class="col-md-4 col-md-offset-0 col-sm-8 col-sm-offset-2 col-xs-10 col-xs-offset-1 text-center">
<p class="asideText">Myeloma is most frequently diagnosed among people aged 65-74.</p>
<div class="statBox statSurv">
<p>Median Age<br/>At Diagnosis</p>
<strong>69</strong>
</div>
</div>
</div>   
            </div>
            <p class="footnote">SEER 18 2011-2015, All Races, Both Sexes</p>
    </div>
 
        <h3>Who Dies From This Cancer?</h3>
        <p> Myeloma is the fourteenth leading cause of cancer death in the United States. The number of deaths was 3.3 per 100,000 men and women per year based on 2011-2015 deaths.</p>
 
<div class="statWrap bar-factSheet">
<strong class="title">Number of Deaths per 100,000 Persons by Race/Ethnicity &amp; Sex: Myeloma </strong>
            <div class="top-statWrap cf">
             
                <!-- Default Display of Data -->
<div class="defaultData cf tabletShow">
<div class="scrapeTable halfSize">
<h5>Males</h5>
<table id="scrapeTable_07">
<tr>
<th scope="row" width="60%"><strong>All Races</strong></th>
<td>4.2</td>
</tr>
<tr>
<th scope="row"><strong>White</strong></th>
<td>4.0</td>
</tr>
<tr>
<th scope="row"><strong>Black</strong></th>
<td>7.5</td>
</tr>
<tr>
<th scope="row"><strong>Asian/Pacific Islander</strong></th>
<td>2.0</td>
</tr>
<tr>
<th scope="row"><strong>American Indian/Alaska Native</strong></th>
<td>3.4</td>
</tr>
<tr>
<th scope="row"><strong>Hispanic</strong></th>
<td>3.4</td>
</tr>
<tr>
<th scope="row"><strong>Non-Hispanic</strong></th>
<td>4.3</td>
</tr>
</table>
</div>
              <div class="scrapeTable halfSize">
<h5>Females</h5>
<table id="scrapeTable_08">
<tr>
<th scope="row" width="60%"><strong>All Races</strong></th>
<td>2.7</td>
</tr>
<tr>
<th scope="row"><strong>White</strong></th>
<td>2.4</td>
</tr>
<tr>
<th scope="row"><strong>Black</strong></th>
<td>5.5</td>
</tr>
<tr>
<th scope="row"><strong>Asian/Pacific Islander</strong></th>
<td>1.3</td>
</tr>
<tr>
<th scope="row"><strong>American Indian/Alaska Native</strong></th>
<td>2.7</td>
</tr>
<tr>
<th scope="row"><strong>Hispanic</strong></th>
<td>2.3</td>
</tr>
<tr>
<th scope="row"><strong>Non-Hispanic</strong></th>
<td>2.7</td>
</tr>
</table>
</div>
</div>
<!--------------------------->
             
                <!-- Use Default Display Data to Generate... -->
<div class="svgEnhance cf tabletHide" aria-hidden="true">
<!-- NEW SVG HERE INSTEAD OF OLD METHOD -->
<div class="topcap"><img class="male" src="/i/factsheets/bargraph_male.jpg" alt="Males" /><img class="female" src="/i/factsheets/bargraph_female.jpg" alt="Females" /></div>
<ul id="eagleChart-02">
<li><span id="ec02m01"><div class="svg-wrap default-bar"><svg id="ec02m01-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">All Races</span><span id="ec02f01"><div class="svg-wrap default-bar"><svg id="ec02f01-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec02m02"><div class="svg-wrap default-bar"><svg id="ec02m02-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">White</span><span id="ec02f02"><div class="svg-wrap default-bar"><svg id="ec02f02-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec02m03"><div class="svg-wrap default-bar"><svg id="ec02m03-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Black</span><span id="ec02f03"><div class="svg-wrap default-bar"><svg id="ec02f03-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec02m04"><div class="svg-wrap default-bar"><svg id="ec02m04-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Asian /<br/>Pacific Islander</span><span id="ec02f04"><div class="svg-wrap default-bar"><svg id="ec02f04-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec02m05"><div class="svg-wrap default-bar"><svg id="ec02m05-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">American Indian /<br/>Alaska Native</span><span id="ec02f05"><div class="svg-wrap default-bar"><svg id="ec02f05-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li><span id="ec02m06"><div class="svg-wrap default-bar"><svg id="ec02m06-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Hispanic</span><span id="ec02f06"><div class="svg-wrap default-bar"><svg id="ec02f06-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li>
<li class="last"><span id="ec02m07"><div class="svg-wrap default-bar"><svg id="ec02m07-graph" viewBox="-5 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span><span class="label">Non-Hispanic</span><span id="ec02f07"><div class="svg-wrap default-bar"><svg id="ec02f07-graph" viewBox="0 0 250 30" preserveAspectRatio="xMinYMin meet" focusable="false"></svg></div></span></li> 
</ul>
<div class="bottomcap"></div>
</div>
                <!--------------------------------------------->
               
            </div>
<p class="footnote">U.S. 2011-2015, Age-Adjusted</p>
</div>
 
      <div class="statWrap whogets-factSheet">
      <strong class="title">Percent of Deaths by Age Group: Myeloma</strong>
            <div class="top-statWrap">
            <div class="row"> 
<div class="col-md-8">
 
<!-- Default Display of Data -->
<div class="defaultData tinyShow">
<div class="scrapeTable">
<table id="scrapeTable_06">
<thead>
<tr>
<th scope="col">Age Range</th>
<th scope="col">Percent of Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20</td>
<td>0.0%</td>
</tr>
<tr>
<td>20-34</td>
<td>0.1%</td>
</tr>
<tr>
<td>35-44</td>
<td>0.9%</td>
</tr>
<tr>
<td>45-54</td>
<td>5.1%</td>
</tr>
<tr>
<td>55-64</td>
<td>15.6%</td>
</tr>
<tr>
<td>65-74</td>
<td>27.4%</td>
</tr>
<tr>
<td>75-84</td>
<td>32.3%</td>
</tr>
<tr>
<td>&gt;84</td>
<td>18.7%</td>
</tr>
</tbody>
</table>
</div>
</div>
<!-------------------------->
<!-- Use Default Display Data to Generate... -->
    <div class="svgEnhance cf tinyHide" aria-hidden="true">
<div class="whiteBox">
<div class="svg-wrap default-new">
<div id="svg-graph-06-wrapper">
  <svg id="svg-graph-06" viewBox="0 0 400 275" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
</div>
</div>
<!--------------------------------------------->
</div>
<div class="col-md-4 col-md-offset-0 col-sm-8 col-sm-offset-2 col-xs-10 col-xs-offset-1 text-center">
<p class="asideText">The percent of myeloma deaths is highest among people aged 75-84.</p>
<div class="statBox statDie">
<p>Median Age<br/>At Death</p>
<strong>75</strong>
</div>
</div>
</div>   
            </div>
          <p class="footnote">U.S. 2011-2015, All Races, Both Sexes</p>
  </div>
 
  </div>
 
    <h2 class="tog-control">Trends in Rates</h2>
    <div class="tog-content">
        <h3>Changes Over Time</h3>
        <p>Keeping track of the number of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.</p>       
      <p>Using statistical models for analysis, rates for new myeloma cases have been rising on average 0.9% each year over the last 10 years. Death rates have been falling on average 0.5% each year over 2006-2015. 5-year survival trends are shown below.</p>
 
        <div class="statWrap trends-factSheet">
            <strong class="title">New Cases, Deaths and 5-Year Relative Survival</strong>
            <div class="top-statWrap cf">
<!-- Use Default Display Data to Generate... -->
<div class="svgEnhance cf tinyHide" aria-hidden="true">
<div class="whiteBox">
<div class="svg-wrap default-glance">
<div id="svg-graph-09-wrapper">
  <svg id="svg-graph-09" class="thick-lines" viewBox="0 0 805 300" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
<div id="legend_svg-graph-09" class="legend-inline"></div>
<p class="footnote">New cases come from SEER 9 Incidence.  Deaths come from U.S. Mortality. 1975-2015, All Races, Both Sexes. Rates are Age-Adjusted.<br/> Modeled trend lines were calculated from the underlying rates using the <a href="https://surveillance.cancer.gov/joinpoint/">Joinpoint Trend Analysis Software.</a></p>
</div>
</div>
<!-- Use Default Display Data to Generate... -->
<div class="svgEnhance cf tinyHide" aria-hidden="true">
<div class="whiteBox">
<div class="svg-wrap default-glance">
<div id="svg-graph-10-wrapper">
  <svg id="svg-graph-10" class="thick-lines" viewBox="0 0 805 300" preserveAspectRatio="xMinYMin meet" focusable="false"></svg>
</div>
</div>
<div id="legend_svg-graph-10" class="legend-inline"></div>
<p class="footnote">SEER 9 5-Year Relative Survival Percent from 1975-2010, All Races, Both Sexes.<br/> Modeled trend lines were calculated from the underlying rates using the <a href="https://analysistools.nci.nih.gov/jpsurv/">Joinpoint Survival Model Software.</a></p>
</div>
</div>
 
              <!--------------------------------------------->
              <a href="#" class="showData-btn-1" data-toggle="modal" data-target="#showData1">View Data Table</a>
    </div>
    </div>
  </div>
<h2 class="tog-control">More About This Cancer</h2>
<div class="tog-content">
<div class="row">
<h3>Myeloma</h3>
<div class="figureCol">
  <!-- Markup for Image -->
<div class="modalItem">
<figure>
<div class="modalItem-trigger">
<a href="#" data-toggle="modal" data-target="">
<div class="figWrap">
<img src="/i/factsheets/mulmy-sm.jpg" alt="Illustration of myeloma cells."/>
</div>
<figcaption><strong>Figure: Myeloma Cells</strong><br/>
<span class="smaller">Click to enlarge.</span></figcaption>
</a>
</div>
</figure>
<div class="modalItem-content">
<div class="modalItem-title">Figure: Myeloma Cells</div>
<div class="modalItem-body">
<div class="center">
<img src="/i/factsheets/mulmy-lg.jpg" alt="">
</div>
<p>Figure: A Myeloma cell (abnormal plasma cell) making M proteins. M proteins are antibodies created by a Myeloma cell.</p>
</div>
</div>
</div>
</div>
 
<p>This type of cancer begins in plasma cells (white blood cells that produce antibodies). It is also called Kahler disease, myelomatosis, and plasma cell myeloma. Plasma cells are white blood cells that make <em>antibodies</em>. Antibodies are part of the <em>immune system</em>. They work with other parts of the immune system to help protect the body from germs and other harmful substances. Each type of plasma cell makes a different antibody. </p>
<p> Myeloma begins when a plasma cell becomes abnormal. The abnormal cell divides to make copies of itself. These abnormal plasma cells are called myeloma cells.</p>
<p> In time, myeloma cells collect in the bone marrow. They may damage the solid part of the bone. When myeloma cells collect in several of your bones, the disease is called &quot;multiple myeloma.&quot; This disease may also harm other tissues and organs, such as the kidneys.</p>
<p>Myeloma cells make antibodies called <em>M proteins</em> and other proteins. These proteins can collect in the blood, urine, and organs.</p>
<p><strong>Additional Information</strong></p>
<ul>
<li><p><a href="https://www.cancer.gov/cancertopics/types/myeloma">Learn more about multiple myeloma</a></p></li>
</ul>
 
<h3>More Information</h3>
 
<p>Here are some resources for learning more about myeloma.</p>
<ul>
<li><a href="https://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient#Keypoint8">More about risk factors for myeloma</a></li>
<li><a href="https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/all">More about the diagnosis of myeloma</a></li>
<li><a href="https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/all">More about treatment options for myeloma</a></li>
<li><a href="https://www.cancer.gov/clinicaltrials">More about clinical trials</a></li>
<li><a href="https://www.cancer.gov/cancertopics/pdq/prevention/overview/patient">More about cancer prevention</a></li>
</ul>
   
<h3>References</h3>
<p>All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within:</p>
<p class="pub">Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, <a href="https://seer.cancer.gov/csr/">https://seer.cancer.gov/csr/1975_2015/</a>, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.</p>
 
<h3>Suggested Citation</h3>
<p>All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.</p>
<p>SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD, <a href="https://seer.cancer.gov/statfacts/html/mulmy.html">https://seer.cancer.gov/statfacts/html/mulmy.html</a></p>
</div>
    </div>
 
<div class="note">
<p>These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse the <a href="https://seer.cancer.gov/csr/">SEER Cancer Statistics Review</a>. To see statistics for a specific state, go to the <a href="https://statecancerprofiles.cancer.gov/">State Cancer Profiles</a>.</p>
<p>The statistics presented in these stat facts are based on the most recent data available, most of which can be found in the <a href="https://seer.cancer.gov/csr/">SEER Cancer Statistics Review</a>. In some cases, different year spans may be used. Estimates for the current year are based on past data.</p>
<p>Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.</p>
</div>
</div><!--/body_content-->        </main>
        </div><!--close row-->
    <img src="/i/right-body.png" alt="" class="bg-back"></div>
   
    <div class="wrapper">
        <meta http-equiv="last_modified" content="Tue, 24 Jul 2018 14:24:49 -0400" />
    </div>
</div>
 
<!-- Blue Footer -->
<footer class="footer" role="contentinfo">
<div class="container">
    <div class="row">
    <div class="col-md-10 col-md-offset-1">
<p class="seer-logo">SEER is supported by the <a href="https://surveillance.cancer.gov/">Surveillance Research Program (SRP)</a> in NCI's <a href="https://cancercontrol.cancer.gov/">Division of Cancer Control and Population Sciences (DCCPS)</a>. SRP provides national leadership in the science of cancer surveillance as well as analytical tools and methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based statistics.</p>
</div>
        </div>
</div>
<div class="footer-links">
    <div class="container">
<div class="row links-col">
<div class="col-sm-3">
<h2>Follow SEER</h2>
<ul class="social">
<li><a href="https://twitter.com/NCICancerStats"><img src="/i/twitter.png" alt="Twitter"></a></li>
<li><a href="https://surveillance.cancer.gov/blog"><img src="/i/blog-icon.png" alt="SRP Blog"></a></li>
</ul>
</div>
<div class="col-sm-3">
<h2>Contact Information</h2>
<ul>       
<li><a href="/about/contact.html">Contact Us</a></li>
<li><a href="https://livehelp.cancer.gov/">LiveHelp Online Chat</a></li>
</ul>
</div>
<div class="col-sm-3">
<h2>More Information</h2>
<ul>   
<li><a href="https://surveillance.cancer.gov/jobs/">Careers</a></li>
<li><a href="/sitemap.html">Sitemap</a></li>
<li><a href="/about/using-website.html">Using This Website</a></li>
</ul>
</div>
<div class="col-sm-3">
<h2>Policies</h2>
<ul>       
<li><a href="https://www.cancer.gov/policies/accessibility">Accessibility</a></li>
<li><a href="https://www.cancer.gov/policies/disclaimer">Disclaimer</a></li>
<li><a href="https://www.cancer.gov/policies/foia">FOIA</a></li>
<li><a href="https://www.cancer.gov/policies/privacy-security">Privacy &amp; Security</a></li>
<li><a href="https://www.cancer.gov/policies/copyright-reuse">Reuse of Graphics and Text</a></li>
<li><a href="https://www.cancer.gov/policies/linking">Website Linking</a></li>
</ul>
</div>
</div>
 
<ul class="linkList">
<li><a href="https://www.hhs.gov/">U.S. Department of Health and Human Services</a></li>
<li><a href="https://www.nih.gov/">National Institutes of Health</a></li>
<li><a href="https://www.cancer.gov/">National Cancer Institute</a></li>
<li class="last"><a href="https://www.usa.gov/">USA.gov</a></li>
</ul>
<p class="center">NIH... Turning Discovery Into Health<sup>&reg;</sup></p>
    </div>
</div>
</footer>
 
 
<script type="text/javascript" src="/j/general.js"></script>
<script src="/bootstrap/js/bootstrap.min.js"></script>
 
<script src="/toolbox/javascript/jquery-ui-1.12.1/jquery-ui.min.js" type="text/javascript"></script>
<script src="/j/mnav.js" type="text/javascript"></script>
 
<!-- Go to www.addthis.com/dashboard to customize your tools -->
<script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-58af0e69573f72ef"></script>
<script type="text/javascript" src="/j/addthis_override.js"></script>
 
<!-- NCI WEB ANALYTICS CODE -->
<script src="//static.cancer.gov/webanalytics/WA_DCCPS_PageLoad.js"></script>
 
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-125238734-1"></script>
<script>
  window.dataLayer = window.dataLayer || ;
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());
 
  gtag('config', 'UA-125238734-1');
</script>
<!-- Additional Scripts -->
<script src="/toolbox/javascript/d3/v3.5.16/d3.js" type="text/javascript"></script>
<script src="/toolbox/javascript/nvd3/v1.8.5/nv.d3.min.js" type="text/javascript"></script>
<script src="j/sharedFunctions.js" charset="utf-8"></script>
<script src="j/graphColors.js" charset="utf-8"></script>
<script src="j/simpleLineChart.js" charset="utf-8"></script>
<script src="j/pieChartWithTable.js" charset="utf-8"></script>
<script src="j/factSheetsData.js" charset="utf-8"></script>
<script src="j/statGraphs.js" charset="utf-8"></script>
<script src="j/renderStatGraphs.js" charset="utf-8"></script>
</body>
</html>

Latest revision as of 19:30, 22 February 2019

Abbreviations

ACTH: Adrenocorticotropic hormone, ARR: Aldosterone-renin ratio, CAM: Cellular adhesion molecules, ERCP: Endoscopic retrograde cholangiopancreatography, ESR: Erythrocyte sedimentation rate, CT: Computerized tomography, Fluorescence in situ hybridization, FDG: Fluorodeoxyglucose, FSH: Follicle stimulating hormone, GI: Gastrointestinal, H&E stain: Hematoxylin and eosin stain, LCA: Leukocyte common antigen, LDH: Lactate dehydrogenase, LH: Luteinizing hormone, MEN: Multiple endocrine neoplasia, MRCP: Magnetic resonance cholangiopancreatography, MRI: Magnetic resonance imaging, N/A: Not applicable/Not available, N/L: Normal, PAS stain: Periodic acid–Schiff stain, PET: Position emission tomography, PGP: Protein gene product 9.5, TB: Tuberculosis, U/S: Ultrasound, ZF: Zona fasciculata, ZG: Zona granulosa, ZR: Zona reticularis.

Adrenal Cortex Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Adrenal Adenoma Aldosterone
[1][2][3][4]
  • Iso and low FDG uptake compared with liver
  • Hyperintense on in-phase and hypointense on oppose-phase
Cortisol
[1][5][6][7]
  • Iso and low FDG uptake compared with liver
  • Hyperintense on in-phase and hypointense on oppose-phase
Androgens
[4][8][9][10]
  • Well-defined
  • Solid mass
  • N/A
  • Hyperintense on in-phase and hypointense on oppose-phase
Non-functional
[1][11][12][13]
  • Solid, well defined mass
  • High lipid content and adjacent compression
  • N/A
  • Hyperintense on in-phase and hypointense on oppose-phase
Adrenal Carcinoma
[12][14][15][16][17]
  • N/A
  • Heterogeneous enhancement
  • Heterogeneous mass with intense FDG uptake greater than liver
  • Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted)
Adrenal Hyperplasia
[2][5][4][8][9][15][18][19]
  • N/A
  • Unilateral or bilateral adrenal enlargement or thickening
  • Signaling is same as that of normal adrenal gland
Medulla Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Pheochromocytoma
[20][21][22][23][24]
  • N/A
Neuroblastoma
[15][25][26][27]
  • Large mass
  • May cross midline
  • N/A
Stains positive for:
Ganglioneuroma
[15][28][29][30]
  • N/A
  • N/A
  • Hypointense (T1-weighted)
  • Varied signal (T2-weighted)

Stains positive for:

Stroma Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Lipoma/Myolipoma
[15][31][32][33]
  • N/A
  • N/L
  • N/A
  • High signal
Others Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Tuberculosis
[34][35][36][37][38]
  • N/A
  • Variable
Histoplasmosis
[39][40][41][42][43]
  • N/A
Cysts
[15][44][45][46]
  • N/A
  • Gold standard
  • Circumscribed anechoic or hypoechoic mass
  • N/A
  • High signal
Hematoma
[15][47][48][49]
  • N/A
  • Variable
  • N/A
  • Majority of the cases in neonantal peiod
  • Majority of the cases caused by trauma
Hemangioma
[15][50][51][52]
  • N/A
  • Hyperintensity (T2) hypointensity (T1)
  • Peripheral spotty and centripetal enhancement
  • Majority of the cases diagnosed incidentally
  • Majority of the lesions are non-functional with female pre-dominance
Lymphoma
[15][53][54][55]
  • N/A
  • N/A
Cystic Lymphangioma
[15][56][57][58]
  • N/A
  • N/L
  • N/A
  • T1 hypointense & T2 hyperintense
Teratoma
[15][59][60][61]
  • N/A
  • N/L
  • Heterogeneous
  • Mixed echo (U/S)
  • Heterogeneous
  • Mixed density elements
  • Egg-shell calcification
  • Mild enhancement
  • N/A
  • Mild enhancement
  • Mixed signals (MRI)
Metastases
[15][62][63][64][65]
  • Related to the primary tumor
  • N/A
  • Low signal on T1-weighed MRI and high signal on T2-weighed MRI

OR

  • Isointense on T1- and T2-weighed MRI

References

  1. 1.0 1.1 1.2 Park JJ, Park BK, Kim CK (June 2016). "Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses". Br J Radiol. 89 (1062): 20151018. doi:10.1259/bjr.20151018. PMC 5258164. PMID 26867466.
  2. 2.0 2.1 Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P (August 2015). "Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas". Mol. Cell. Endocrinol. 411: 146–54. doi:10.1016/j.mce.2015.04.022. PMC 4474471. PMID 25958045.
  3. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (May 2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.
  4. 4.0 4.1 4.2 Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C (2013). "Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging". J Clin Imaging Sci. 3: 61. doi:10.4103/2156-7514.124088. PMC 3935261. PMID 24605256.
  5. 5.0 5.1 Stratakis CA (2008). "Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)". Endocr Dev. 13: 117–32. doi:10.1159/000134829. PMC 3132884. PMID 18493137.
  6. Zilbermint M, Stratakis CA (June 2015). "Protein kinase A defects and cortisol-producing adrenal tumors". Curr Opin Endocrinol Diabetes Obes. 22 (3): 157–62. doi:10.1097/MED.0000000000000149. PMC 4560837. PMID 25871963.
  7. Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J (April 2018). "ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures". BMC Endocr Disord. 18 (1): 22. doi:10.1186/s12902-018-0250-6. PMC 5913873. PMID 29685132.
  8. 8.0 8.1 Arnold DT, Reed JB, Burt K (January 2003). "Evaluation and management of the incidental adrenal mass". Proc (Bayl Univ Med Cent). 16 (1): 7–12. PMC 1200803. PMID 16278716.
  9. 9.0 9.1 Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J (2013). "Pure androgen-secreting adrenal adenoma associated with resistant hypertension". Case Rep Endocrinol. 2013: 356086. doi:10.1155/2013/356086. PMC 3681270. PMID 23819074.
  10. Zhou WB, Chen N, Li CJ (January 2019). "A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman". BMC Endocr Disord. 19 (1): 14. doi:10.1186/s12902-019-0342-y. PMC 6343319. PMID 30674304.
  11. Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (October 2016). ""Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study". Ann. Intern. Med. 165 (8): 533–542. doi:10.7326/M16-0547. PMC 5453639. PMID 27479926.
  12. 12.0 12.1 Nieman LK (September 2010). "Approach to the patient with an adrenal incidentaloma". J. Clin. Endocrinol. Metab. 95 (9): 4106–13. doi:10.1210/jc.2010-0457. PMC 2936073. PMID 20823463.
  13. Li B, Guo Q, Yang H, Guan J (January 2013). "Giant non-functional adrenal adenoma: A case report". Oncol Lett. 5 (1): 378–380. doi:10.3892/ol.2012.978. PMC 3525484. PMID 23255953.
  14. Libé R (2015). "Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment". Front Cell Dev Biol. 3: 45. doi:10.3389/fcell.2015.00045. PMC 4490795. PMID 26191527.
  15. 15.00 15.01 15.02 15.03 15.04 15.05 15.06 15.07 15.08 15.09 15.10 15.11 Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T (September 2018). "CT and MRI of adrenal gland pathologies". Quant Imaging Med Surg. 8 (8): 853–875. doi:10.21037/qims.2018.09.13. PMC 6177362. PMID 30306064.
  16. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD (April 2014). "Adrenocortical carcinoma". Endocr. Rev. 35 (2): 282–326. doi:10.1210/er.2013-1029. PMC 3963263. PMID 24423978.
  17. Wang C, Sun Y, Wu H, Zhao D, Chen J (March 2014). "Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers". Histopathology. 64 (4): 567–76. doi:10.1111/his.12283. PMC 4282325. PMID 24102952.
  18. Michelle M A, Jensen CT, Habra MA, Menias CO, Shaaban AM, Wagner-Bartak NA, Roman-Colon AM, Elsayes KM (November 2017). "Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics". Br J Radiol. 90 (1079): 20170330. doi:10.1259/bjr.20170330. PMC 5963387. PMID 28707538. Vancouver style error: name (help)
  19. Zhang Y, Li H (2015). "Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease". Int J Clin Exp Med. 8 (10): 19311–7. PMC 4694469. PMID 26770569.
  20. Martucci VL, Pacak K (2014). "Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment". Curr Probl Cancer. 38 (1): 7–41. doi:10.1016/j.currproblcancer.2014.01.001. PMC 3992879. PMID 24636754.
  21. Kantorovich V, Pacak K (2010). "Pheochromocytoma and paraganglioma". Prog. Brain Res. 182: 343–73. doi:10.1016/S0079-6123(10)82015-1. PMC 4714594. PMID 20541673.
  22. Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV (November 2009). "Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus)". Vet. Pathol. 46 (6): 1221–9. doi:10.1354/vp.09-VP-0022-M-FL. PMID 19605896.
  23. Kantorovich V, Eisenhofer G, Pacak K (December 2008). "Pheochromocytoma: an endocrine stress mimicking disorder". Ann. N. Y. Acad. Sci. 1148: 462–8. doi:10.1196/annals.1410.081. PMC 2693284. PMID 19120142.
  24. Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
  25. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG (October 2014). "Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project". J. Clin. Oncol. 32 (28): 3169–76. doi:10.1200/JCO.2014.56.1621. PMC 4171360. PMID 25154816.
  26. Bordbar M, Tasbihi M, Kamfiroozi R, Haghpanah S (2014). "Epidemiological and clinical characteristics of neuroblastoma in southern iran". Iran J Ped Hematol Oncol. 4 (3): 89–96. PMC 4173027. PMID 25254086.
  27. Skoura E, Oikonomopoulos G, Vasileiou S, Kyprianou D, Koumakis G, Datseris IE (2014). "(18)F-FDG-PET/CT, (123)I-MIBG and (99m)Tc-MDP whole-body scans, in detecting recurrence of an adult adrenal neuroblastoma". Hell J Nucl Med. 17 (1): 58–61. doi:10.1967/s002449910116. PMID 24563879.
  28. Mylonas KS, Schizas D, Economopoulos KP (October 2017). "Adrenal ganglioneuroma: What you need to know". World J Clin Cases. 5 (10): 373–377. doi:10.12998/wjcc.v5.i10.373. PMC 5648998. PMID 29085827.
  29. Adas M, Koc B, Adas G, Ozulker F, Aydin T (April 2014). "Ganglioneuroma presenting as an adrenal incidentaloma: a case report". J Med Case Rep. 8: 131. doi:10.1186/1752-1947-8-131. PMC 4031973. PMID 24779851.
  30. Li J, Yang CH, Li LM (April 2013). "Diagnosis and treatment of 29 cases of adrenal ganglioneuroma". Eur Rev Med Pharmacol Sci. 17 (8): 1110–3. PMID 23661526.
  31. Lam KY, Lo CY (September 2001). "Adrenal lipomatous tumours: a 30 year clinicopathological experience at a single institution". J. Clin. Pathol. 54 (9): 707–12. PMC 1731508. PMID 11533079.
  32. Gershuni VM, Bittner JG, Moley JF, Brunt LM (January 2014). "Adrenal myelolipoma: operative indications and outcomes". J Laparoendosc Adv Surg Tech A. 24 (1): 8–12. doi:10.1089/lap.2013.0411. PMC 3931430. PMID 24328509.
  33. Luo J, Chen L, Wen Q, Xu L, Chu S, Wang W, Alnemah MM, Fan S (2015). "Lipoadenoma of the adrenal gland: report of a rare entity and review of literature". Int J Clin Exp Pathol. 8 (8): 9693–7. PMC 4583971. PMID 26464739.
  34. Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG (2016). "Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test". Int J Endocrinol. 2016: 9051865. doi:10.1155/2016/9051865. PMC 4781954. PMID 27006656.
  35. Haddara WM, van Uum SH (September 2004). "TB and adrenal insufficiency". CMAJ. 171 (7): 710, author reply 710–1. doi:10.1503/cmaj.1041046. PMC 517840. PMID 15451821.
  36. Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW (October 2015). "Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status". World J Radiol. 7 (10): 336–42. doi:10.4329/wjr.v7.i10.336. PMC 4620114. PMID 26516430.
  37. Vinnard C, Blumberg EA (January 2017). "Endocrine and Metabolic Aspects of Tuberculosis". Microbiol Spectr. 5 (1). doi:10.1128/microbiolspec.TNMI7-0035-2016. PMID 28233510.
  38. Rajasekharan C, Ajithkumar S, Anto V, Parvathy R (May 2013). "Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine". BMJ Case Rep. 2013. doi:10.1136/bcr-2012-008011. PMID 23687365.
  39. Rog CJ, Rosen DG, Gannon FH (December 2016). "Bilateral adrenal histoplasmosis in an immunocompetent man from Texas". Med Mycol Case Rep. 14: 4–7. doi:10.1016/j.mmcr.2016.11.006. PMC 5154969. PMID 27995051.
  40. Wahab NA, Mohd R, Zainudin S, Kamaruddin NA (2013). "Adrenal involvement in histoplasmosis". EXCLI J. 12: 1–4. PMC 4817423. PMID 27047312.
  41. May D, Khaled D, Gills J (July 2018). "Unilateral adrenal histoplasmosis". Urol Case Rep. 19: 54–56. doi:10.1016/j.eucr.2018.03.010. PMC 5991316. PMID 29888193.
  42. Gupta RK, Majumdar K, Srivastava S, Varakanahalli S, Saran RK (2018). "Endoscopic Ultrasound-guided Cytodiagnosis of Adrenal Histoplasmosis with Reversible CD4 T-Lymphocytopenia and Jejunal Lymphangiectasia". J Cytol. 35 (2): 110–113. doi:10.4103/JOC.JOC_234_15. PMC 5885598. PMID 29643659.
  43. Padma S, Sreehar S (May 2014). "18F FDG PET/CT identifies unsuspected bilateral adrenal histoplasmosis in an elderly immuno compromised patient". Indian J. Med. Res. 139 (5): 786–7. PMC 4140048. PMID 25027093.
  44. Carsote M, Ghemigian A, Terzea D, Gheorghisan-Galateanu AA, Valea A (2017). "Cystic adrenal lesions: focus on pediatric population (a review)". Clujul Med. 90 (1): 5–12. doi:10.15386/cjmed-677. PMID 28246490.
  45. Słapa RZ, Jakubowski WS, Dobruch-Sobczak K, Kasperlik-Załuska AA (December 2015). "Standards of ultrasound imaging of the adrenal glands". J Ultrason. 15 (63): 377–87. doi:10.15557/JoU.2015.0035. PMC 4710689. PMID 26807295.
  46. Olaoye IO, Adesina MD, Afolayan EA (June 2018). "A giant adrenal cyst with an uncertain preoperative diagnosis causing a dilemma in management". Clin Case Rep. 6 (6): 1074–1076. doi:10.1002/ccr3.1519. PMC 5986023. PMID 29881567.
  47. Hamilton D, Harris MD, Foweraker J, Gresham GA (February 2004). "Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection". J. Clin. Pathol. 57 (2): 208–9. PMC 1770213. PMID 14747454.
  48. Di Serafino M, Severino R, Coppola V, Gioioso M, Rocca R, Lisanti F, Scarano E (September 2017). "Nontraumatic adrenal hemorrhage: the adrenal stress". Radiol Case Rep. 12 (3): 483–487. doi:10.1016/j.radcr.2017.03.020. PMC 5551907. PMID 28828107.
  49. Ierardi AM, Petrillo M, Patella F, Biondetti P, Fumarola EM, Angileri SA, Pesapane F, Pinto A, Dionigi G, Carrafiello G (April 2018). "Interventional radiology of the adrenal glands: current status". Gland Surg. 7 (2): 147–165. doi:10.21037/gs.2018.01.04. PMC 5938278. PMID 29770310.
  50. Alhajri K, Alhasan I, Alzerwi N, Abudaff N (April 2011). "Adrenal haemangioma". BMJ Case Rep. 2011. doi:10.1136/bcr.12.2010.3604. PMC 3079485. PMID 22701011.
  51. Iwamoto G, Shimokihara K, Kawahara T, Takamoto D, Yao M, Teranishi JI, Otani M, Uemura H (2018). "Adrenal Hemangioma: A Case of Retroperitoneal Tumor". Case Rep Med. 2018: 8796327. doi:10.1155/2018/8796327. PMC 5836307. PMID 29560018.
  52. Tarchouli M, Boudhas A, Ratbi MB, Essarghini M, Njoumi N, Sair K, Zentar A (2015). "Giant adrenal hemangioma: Unusual cause of huge abdominal mass". Can Urol Assoc J. 9 (11–12): E834–6. doi:10.5489/cuaj.2967. PMC 4639440. PMID 26600897.
  53. Harada K, Kimura K, Iwamuro M, Terasaka T, Hanayama Y, Kondo E, Hayashi E, Yoshino T, Otsuka F (September 2017). "The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency". Intern. Med. 56 (17): 2261–2269. doi:10.2169/internalmedicine.8216-16. PMC 5635296. PMID 28794358.
  54. Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM (February 2017). "Adrenal lymphoma: presentation, management and prognosis". QJM. 110 (2): 103–109. doi:10.1093/qjmed/hcw174. PMID 27795295.
  55. Karimi F (October 2017). "Primary Adrenal Lymphoma Presenting with Adrenal Failure: A Case Report and Review of the Literature". Int J Endocrinol Metab. 15 (4): e12014. doi:10.5812/ijem.12014. PMC 5750783. PMID 29344029.
  56. Michalopoulos N, Laskou S, Karayannopoulou G, Pavlidis L, Kanellos I (December 2015). "Adrenal Gland Lymphangiomas". Indian J Surg. 77 (Suppl 3): 1334–42. doi:10.1007/s12262-015-1206-y. PMC 4775622. PMID 27011561.
  57. Zhao M, Gu Q, Li C, Yu J, Qi H (2014). "Cystic lymphangioma of adrenal gland: a clinicopathological study of 3 cases and review of literature". Int J Clin Exp Pathol. 7 (8): 5051–6. PMC 4152068. PMID 25197378.
  58. Joliat GR, Melloul E, Djafarrian R, Schmidt S, Fontanella S, Yan P, Demartines N, Halkic N (February 2015). "Cystic lymphangioma of the adrenal gland: report of a case and review of the literature". World J Surg Oncol. 13: 58. doi:10.1186/s12957-015-0490-0. PMC 4335415. PMID 25889625.
  59. Ramakant P, Rana C, Singh KR, Mishra A (2018). "Primary adrenal teratoma: An unusual tumor - Challenges in diagnosis and surgical management". J Postgrad Med. 64 (2): 112–114. doi:10.4103/jpgm.JPGM_588_16. PMC 5954807. PMID 29067922.
  60. Li S, Li H, Ji Z, Yan W, Zhang Y (November 2015). "Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults". Oncol Lett. 10 (5): 2865–2870. doi:10.3892/ol.2015.3701. PMC 4665718. PMID 26722254.
  61. Zhou L, Pan X, He T, Lai Y, Li W, Hu Y, Ni L, Yang S, Chen Y, Lai Y (October 2018). "Primary adrenal teratoma: A case series and review of the literature". Mol Clin Oncol. 9 (4): 437–442. doi:10.3892/mco.2018.1687. PMC 6125700. PMID 30214733.
  62. Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K (November 2004). "Large bilateral adrenal metastases in non-small cell lung cancer". World J Surg Oncol. 2: 37. doi:10.1186/1477-7819-2-37. PMC 535544. PMID 15541184.
  63. ABRAMS HL, SPIRO R, GOLDSTEIN N (January 1950). "Metastases in carcinoma; analysis of 1000 autopsied cases". Cancer. 3 (1): 74–85. PMID 15405683.
  64. Gerber E, Dinlenc C, Wagner JR (2004). "Laparoscopic adrenalectomy for isolated adrenal metastasis". JSLS. 8 (4): 314–9. PMC 3016821. PMID 15554272.
  65. Vaughan ED (September 1998). "Diagnosis and management of surgical adrenal disorders". Int. J. Urol. 5 (5): 401–17. PMID 9781426.